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ORGAN SPECIFIC VASCULAR RESPONSE TO ANGIOPOIETIN 2 AFFECTS 
BREAST CANCER METASTATIC ORGANOTROPISM 
 
Eliot Sananikone Fletcher, MPH, Ph.D.* 
Advisory Professor: Raghu Kalluri, MD, Ph.D. 
 
The solid tumor microenvironment, pre-metastatic niche, and fibrotic 
environment are known to have significant biochemical and biomechanical 
similarities to the fibrotic environment. All have significantly increased levels of 
factors such as TGFβ, HIF1α, TNFα, PDGF, VEGF, FGF, interleukins and other 
growth factors that are known to be pro-tumorigenic. Clinical and basic science 
research has shown that fibrosis presents an environment that favors tumor 
growth, such as hepatocellular carcinoma being commonly preceded by liver 
cirrhosis, or bleomycin induced lung fibrosis enhancing pulmonary metastasis in 
mouse models of breast cancer. In addition to the evidence indicating that fibrosis 
enhances primary tumor growth and metastasis it is also well characterized that 
primary tumor metastasis has specific organotropism, for example breast cancer 
commonly spreads to the lungs, brain, bone, liver and lymph nodes. However, 
whether non-organtropic f ibrosis can redirect metastasis to the damaged organ 
has not been investigated.  
To elucidate the fibrotic effect on tumor organotropism we induced fibrosis 
in the organotropic lungs and in the non-organotropic kidney of two mouse models 
of breast cancer, the 4T1 murine cancer cell line model and the genetic MMTV-
Pymt model, both of which are known to metastasize. Using histopathology, 
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microarrays, gene expression by polymerase chain reaction, ELISA, chemokine 
array, and in vitro experiments we demonstrate that despite the pro-tumorigenic 
environment, kidney fibrosis does not redirect metastasis to the non-organotropic 
damaged organ. However, mice with kidney fibrosis had increased metastasis to 
their lungs. Furthermore, we found that kidney fibrosis increases the circulating 
levels of the pro-angiogenic factor Angiopoietin 2 that increased vascular 
permeability of the lungs, but not the kidneys. In fact, while fibrotic lungs showed 
decreased expression of endothelial tight gap junction protein Claudin-5, the 
fibrotic kidneys had an elevated expression of Claudin-5.  
Our findings suggest that despite the similarities between fibrosis, the 
tumor microenvironment and the pre-metastatic niche, that while it can enhance 
tropic metastatic disease, it cannot redirect organotropism indicating that other 
factors must be involved in directing organotropism. Here we report t hat tumor 
organotropism may be a result of organ specific vascular responses to excess 
circulating factors and increased fibrotic factors . These findings indicate that 
organotropism is directly related to and as a result of organ specific vascular 
alterations.  
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Chapter 1 
Background and Significance 
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Metastatic disease 
 
Metastatic disease is the leading cause of mortality in patients diagnosed with 
cancer (Patrick Mehlen and Alain Puisieux 2006, Li and King 2012). It is estimated that 
metastatic disease is responsible for 90% of human cancer deaths (Li and King 2012). In 
2016 1,685,210 people were diagnosed with cancer in the United States alone, 595,690 
died from that diagnosis (National Institute of Health). Therefore 536,121 people died due to 
metastatic disease in the United States in 2016. Globally, 7.38 million people died from 
metastatic disease in 2012 (World Health Organization). Although metastatic disease 
occurs in almost all cancer types including the hematological cancers, breast cancer 
metastasis is one of the more readily researched and characterized pathologies. According 
to the National Cancer Institute there are 246,660 new cases of female and male breast 
cancer a year and 40,450 deaths (National Institute of Health). With modern preventative 
measures such as early mammography it is possible to detect primary breast tumors before 
they become malignant. Early detection measures with breast cancer allow for the surgical 
removal of breast cancer tissue either by resection or in more advanced cases mastectomy. 
While resection and mastectomy have scarification outcomes, these can be fixed by plastic 
surgery and loss of breast tissue does not place life threatening burden on the patient. 
However, if breast cancer cells metastasize to organs required for the sustainment of the 
organism this can impose a life threatening diagnosis, meaning that 100% of breast cancer 
deaths are due to metastasis. Thus the early detection of breast cancer since the late 1990s 
has significantly reduced the numbers of breast cancer related mortalities. However, 
metastasis from breast cancer and other cancer diagnosis remains the primary cause of 
cancer patient mortality (Bleyer and Welch 2013).  
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The process of metastasis follows a defined route based around fundamental 
anatomy and the location of the primary tumor (Figure 1) (Fidler 2003). Based on 
Kundson’s Two hit hypothesis (Knudson 2000), two genetic mutations are required to occur 
in a cell that prompts the uncontrolled proliferation of that cell. The loss of a tumor 
suppressor and the gain of an oncogene are deemed sufficient to begin neoplastic 
formation. Initial formation of hyperplastic tissue begins the process of further genomic 
mutation which in turn begets even more genetic mutations (genomic instability), leading to 
dysplasia and cancer in situ (Gordon 2010). The increase in mutations acts as a Darwinian 
survival mechanism allowing the strongest tumor cells to survive and uncontrollably 
propagate (Pepper and Maley 2009). Most commonly this occurs in epithelial tissue which is 
separated from the surrounding stroma and vasculature by a basement membrane. 
Approximately 80-90% of tumors are epithelial in origin, the hematologic cancers make up 
8%, and cancer of the connective tissue is around 1-2% of cancer diagnosis (National 
Cancer Institute). All three types of cancer are known to undergo metastasis. As the tumor 
continues to progress it can begin to invade through the basement membrane by secreting 
matrix metalloproteinases that can degrade extracellular matrix proteins (Peinado and 
Lyden 2011). Once the basement membrane has been breached cells from the primary 
tumor may cross the endothelial cell wall into the circulation via paracellular transendothelial 
migration, also known as intravasation (Junqueira and Avraham 2011).  
In addition to degrading basement membrane via the secretion of matrix 
metalloproteinases, tumors also secrete significant angiogenic factors such as vascular 
endothelial growth factor (VEGF), angiopoietins, transforming growth factor β (TGFβ), tumor 
necrosis factor α (TNFα), epidermal growth factor (EGF) and many others (Nishida and 
Kojiro 2006). This continued secretion of proangiogenic factors induces the growth of new 
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vasculature within and around the tumor. However, unlike healthy organ vasculature, tumor 
vasculature is dysregulated and malformed often leading to leaky vessels, poor perfusion, 
and diminished immune cell trafficking (Siemann 2011, Keskin and Kalluri 2013). Tumor 
vascular dysregulation increases the hypoxic environment of the tumor and perpetuates the 
survival of tumor cells that will be more likely to survive in austere conditions such as the 
circulatory system. It also presents a route for tumor cells to more easily enter the 
circulation and travel to distant organ sites (Siemann 2011).  
Once tumor cells enter the circulation they are known as circulating tumor cells. 
Within the circulation these cells have to survive stresses that epithelial cells are not 
typically exposed to such as high shear stress from blood flow (Joosse and Pantel 2014). 
The malignant epithelial cells have to undergo a number of changes prior to entering the 
circulation that increases their capacity to survive. For example, healthy epithelial cells 
require attachments to adjacent cells via tight gap junctions, adherent junctions and/or 
desmosomes. The loss of these connections can result in apoptosis or autophagy due to 
anoikis (Gilmore 2005). Most cells within the body require cell-cell attachments to maintain 
survival signals with the exception of hematological cells such as red blood cells and 
immune cells. However, tumorigenic cells have typically undergone a process known as 
epithelial-to-mesenchymal transition that allows them survive in the absence of cell contact 
(Frisch and Cieply 2013).  
If the tumor cell is able to survive the circulatory stresses it must then adhere to the 
luminal side of the endothelial cells, and again transport across the endothelial barrier by 
parracellular transendothelial migration in a process called extravasation (Li and King 2012, 
Boelte and Ling 2010). If a circulating tumor cell is able to extravasate into the parenchymal 
space of an organ that disseminated cancer cell may either lay dormant or begin 
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proliferating into a metastasis. Whether dormant or proliferative, disseminated cancer cells 
must undergo a mesenchymal-to-epithelial transition (the reverse of EMT) and anchor 
themselves to the organ in which they have extravasated (Gunasinghe and Hugo 2012). 
Under the correct circumstances, growth factors etc. these cells may develop into life 
threatening metastatic disease. Given the multi-step process of the metastatic cascade it is 
a highly inefficient process with less than 0.01% of circulating tumor cells shed from the 
primary tumor ultimately able of developing a distant organ metastasis (Fidler 1970, Fidler 
2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic of the Metastatic Cascade. The process of metastasis consists of multiple stages 
each considered rate limiting. (Arshad, F., L. Wang, C. Sy, S. Avraham and H. K. Avraham (2010). 
"Blood-brain barrier integrity and breast cancer metastasis to the brain." Patholog Res Int 2011: 
920509). This is an open access article distributed under the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original 
work is properly cited. 
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Organotropism 
Metastatic organotropism is the propensity for tumors of a specific origin to spread to 
specific organs (National Cancer Institute). Based on basic science research, clinical 
reports, and pathology reports the National Cancer Institute reports the following likely 
metastatic organotropic organs for their primary cancer type (National Cancer Institute): 
Cancer type Main sites of metastasis* 
Bladder Bone, liver, lung 
Breast Bone, brain, liver, lung 
Colorectal Liver, lung, peritoneum 
Kidney Adrenal gland, bone, brain, liver, lung 
Lung Adrenal gland, bone, brain, liver, other lung 
Melanoma Bone, brain, liver, lung, skin/muscle 
Ovary Liver, lung, peritoneum 
Pancreas Liver, lung, peritoneum 
Prostate Adrenal gland, bone, liver, lung 
Stomach Liver, lung, peritoneum 
Thyroid  Bone, liver, lung 
Uterus Bone, liver, lung, peritoneum, vagina 
 
 
In 1889 Dr. Steven Paget proposed that certain primary tumors had specific 
metastatic tropism for specific organs, dubbed the seed-and-soil hypothesis. Paget stated 
that tumors of specific origin release circulating tumor cells, the seeds, which can only grow 
in a certain organ, the soil, based on the homeostatic factors found there. By performing 
autopsies on patients he observed a non-random spread from primary tumors to specific 
organs and deduced that this specific tumor organotropism was due to his seed-and-soil 
hypothesis (Paget 1889).  
Figure 2: National Cancer Institute’s list of sites that cancer most commonly spread to from the 
primary tumor.  (National Cancer Institute. About Cancer. (n.d.). Retrieved August 07, 2016, from 
http://www.cancer.gov/about-cancer) 
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In the early 1900s a pathologist named Dr. Irving Zeidman found that circulating 
tumor cells of specific tumor types had different morphological appearance and that certain 
morphologies permitted the crossing of the endothelial capillary barrier leading to metastatic 
growth (Ewing 1928). The observation that differing tumors release circulating tumor cells 
with different morphologies leant to the seed-and-soil hypothesis in that certain 
morphologies would be more likely to form emboli and more easily cross the endothelial 
barrier and extravasate. These were not homogenous populations of circulating tumors cells 
however and some cells did not appear to have the morphological attributes that would 
allow them to cross the endothelial barrier (Ewing 1928). This observation was one of the 
first examples of tumor heterogeneity and would be followed up with significant research 
over the next hundred years showing that tumors are not clonal populations deriving from a 
single dysplastic cell.  
Tumor heterogeneity is defined by the fact that tumors do not generally consist of 
clonal cells derived from a parent cell with X number of mutations, but rather a number of 
different neoplastic cells with varying mutations conferring differing Darwinian survival 
advantages (Marusyk and Polyak 2010). Based on the different pressures placed on the 
cancer cells in the primary tumor such as hypoxia, excess lactic acid content, changes in 
pH, different mutations will confer survival advantages that if left untreated will eventually 
form into the ability to metastasize (Pepper and Maley 2009). Within a tumor different areas 
are subject to different pressures, and within each organ these pressures are different, and 
within an individual patient these pressures are further diverse. This multi-level difference in 
selective pressures results in cancer in each patient being different from that of another 
patient, even with a similar diagnosis. In large part this is the basis for today’s research into 
more focused genetic therapies to target driver mutations. The heterogeneity of tumors 
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further indicates that the cells that are able to metastasize are also heterogeneous in 
nature, meaning that not all cells that metastasize are clonal either (Nowell 1976). However, 
research has shown that despite heterogeneous emboli in the circulation the metastatic 
tumors of melanoma where in fact clonally derived from a single parent cell (Talmadge 
1982). This is additional evidence that only certain cells derived from the primary tumor 
have the ability to survive and proliferate after leaving the primary tumor. This tumor 
heterogeneity was further evidence that the cells able to enter the circulation had conferred 
survival mechanisms that allowed them to propagate in specific environments, and thus 
added weight to the seed-and-soil hypothesis. When all this evidence is amalgamated the 
seed-and-soil hypothesis can be simply stated as cancer that can “metastasize to locations 
that are biochemically and physiologically favorable for implantation and growth 
(Ramakrishna 2013).” 
In 1980 Dr. Isiah Fidler published a seminal paper supporting the seed-and-soil 
hypothesis (Fidler 1982). After having worked with Dr. Irving Zeidman, Dr. Fidler performed 
experiments in which he injected B16-F10 cells intravenously, subcutaneously or 
intramuscular and observed their metastatic spread. The B16-F10 tumor cell line is a 
melanoma line that underwent serial transplantation to isolate a highly metastatic form of 
murine melanoma. Using both parabiosis and [125l]-5-iodo-2'-deoxyuridine cancer cell 
labelling experiments Dr. Filder observed that despite circulating tumor cells being able to 
reach both the kidneys and the lungs, they would only form metastasis in the lungs (Fidler 
1970). This led the authors to conclude that metastasis did indeed follow the seed-and-soil 
hypothesis given the presence of cancer cells in the kidney, but their inability to proliferate 
due to an unfavorable environment.  
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Prior to the seed-and-soil papers published in the mid-1900s, the predominant 
theory of metastasis was put forth by Dr. James Ewing. In the 1930s Dr. Ewing submitted 
an alternative hypothesis to seed-and-soil pertaining to metastatic disease in that cancer 
cells spread to specific organs due predominantly to the mechanistic nature of the vascular 
system (Ewing 1928). The vascular hypothesis asserted that once a cancer cell was able to 
enter the circulation it would pass through the arteries into arterioles and then capillaries 
and extravasate into parenchymal spaces. The organ that the cancer cell was able to 
extravasate to was immaterial of the primary tumor but due to the nature of vasculature and 
where the cancer cell happened to extravasate. The evidence for this was based primarily 
on research showing that metastatic cells predominantly formed emboli in the capillaries of 
metastatic organs, while similar emboli where found in the arterioles of organs that did not 
form metastasis (Ewing 1928). Ewing proposed that the circulatory framework and 
hemodynamics where responsible for the spread of cancer cells from their primary tumor. 
For example, breast cancer was likely to spread to the lungs because of its proximity to 
vena cava and the pulmonary arteries.  
Recent studies using zebra fish models to visualize extravasation have also shown 
that vascular mechanics are essential for the process of metastasis. Two studies (Stoletov 
2010, Kanada 2014), one by Stoletov et al. in 2010 and Kanada et al. in 2014 showed that 
when cancer cells where injected into zebrafish they could visualize the formation of emboli 
in the arterioles and capillaries. The researchers opted to use zebrafish due to the ease of 
visualization of their vasculature as compared to other animal models with non-opaque 
dermal layers. They also show that the endothelium played an active role in the crossing of 
the cancer cells across the vascular barrier and that when VEGF was depleted the cancer 
cells were unable to intravasate, but could still extravasate.  
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In addition to work in Zebrafish, significant gene research has focused on 
organotropism, predominantly in breast cancer mouse models. Dr. Joan Massagué 
compared the gene expression of human and mouse primary breast tumors in metastasis to 
the bone, lung and brain and identified a number of genes that are associated with organ 
specific metastasis. In their 2009 paper (Bos and Massagué 2009) they identified genes 
that were associated with increased metastatic spread to the brain. The brain possesses a 
particularly stable blood-brain barrier that is highly selective for permeabalization, none the 
less metastatic cells have developed a means by which to cross this barrier, while many 
chemotherapeutic drugs are unable to permeate the blood-brain barrier (Kreuter 2002). It is 
worth noting that a significant number of the genes found in these three different studies are 
overlapping, indicating that they may in fact not explain the organotropism of metastasis. 
The modern study of organotropism has focused primarily on researching the gene 
expression differences between different organs with metastatic disease and has not 
focused on the non-organotropic organs or vascular signatures.  
Both Paget’s and Ewing’s hypothesis offer explanations for the organotropic 
properties of metastatic disease, and much like the nature versus nurture argument it is 
most likely that both contribute to the spread of the disease. Since Paget and Ewing 
significant research has been done on the vasculature indicating that there is in fact organ 
specific differences. Although less well studied, organ specific vasculature may in fact marry 
Paget’s and Ewing’s hypothesis as tumors of specific origin may affect organ specific 
vasculature differently. The result would be different responses in vascular dysregulation in 
varying organs and could contribute to the explanation for cancer tropism. 
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Mouse Models for Metastasis and Organotropism 
To continue the study of metastatic disease varying models have been designed to 
faithfully replicate human metastasis. To date the most accurate models of metastasis are 
found in mice that have transgenic induction of a tumor or are injected with a human or 
mouse metastatic cancer cell line. The majority of transgenic cancer models can accurately 
recreate primary tumor progression, but have been less successful at modelling metastasis 
showing significantly decreased penetrance than in the human counterparts (Francia 2011). 
Human derived cell lines necessitate injection into mice that are devoid of an active immune 
system (NOD/SCID mice) so as to ensure that the tumors are not rejected, and thus 
decreases the replication of the human model. This is especially important given recent 
research showing the involvement of the immune system in tumor progression. There are a 
number of mouse derived cancer cell lines that metastasize and this allows the orthotopic or 
intravenous injection of mice with fully functioning immune systems that are known to 
metastasize (Francia 2011). Although mice do differ from humans, the orthotopic injection of 
mouse derived cancer cell lines does recapitulate the human model and is often used today 
in the lab. Two such cell lines are the melanoma B16-F10 (Hart and Fidler 1980) and the 
mammary fat pad 4T1 (Aslakson 1992, Pulasaki 2001) cell line to model breast cancer. The 
B16-F10 cell was isolated by Dr. Fidler from a spontaneous melanoma that derived in 
Black-6 mice and was serially transplanted from metastasis to produce a highly metastatic 
line. The 4T1 cell line was similarly derived from a spontaneous tumor, this one formed in 
the mammary fat pad of a BALBc mouse and was selected from numerous cells in the 
primary tumor that showed high metastatic potential. There are also cell lines derived from 
this same tumor that show less metastatic potential such as the 67NR cell line highlighting 
the heterogeneous nature of tumors. As mentioned before Dr. Fidler utilized the B16-F10 
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cell line to determine the organotropism of melanoma to the bone, brain, liver, and lungs. 
Similarly, the 4T1 cell line when injected orthotopically has shown metastasis to the bone, 
brain, liver, lung as does breast cancer in human patients. Numerous publications have 
highlighted the spread of the B16-F10 and 4T1 tumor cell lines to their organotropic sites 
providing weight to Paget’s seed-and-soil hypothesis.  
 More recent publications however have highlighted the capabilities of multiple mouse 
cancer cell lines including B16-F10 and 4T1 to grow in non-metastatic sites when injected 
directly or provided mechanistic support to reach non-organotropic site. A 2011 paper by Li 
et al used hydrodynamic injections of B16-F1, 4T1 and Renca renal carcinoma cells to force 
colonization of organotropic and non-organotropic organs. This procedure was typically 
used to study the intravenous injection of DNA or RNAi into mice to illicit a genetic 
phenotype. Hydrodynamic injections use high volume injections of anywhere between 8-
10% of body weight to force an increase in pressure in the inferior vena cava which in turn 
creates high internal hematological pressure. The increase in hemodynamic pressure 
induces systemic endothelial leakage leading to increased extravasation and colonization of 
the lungs, liver and the non-organotropic kidneys with B16-F1 and 4T1 cells. Contrary to the 
findings of the seed-and-soil hypothesis this indicates that given the ability to enter the 
perivascular parenchyma tumors can grow regardless of their etiology. Further evidence for 
this was published in 2013 when Antonio et al. showed that 4T1 mammary fat pad cells 
could be injected directly into the cortex of the kidney and grow and even metastasize from 
the kidney to the lung. They further showed that by damaging the kidney with renal 
ischemia reperfusion experiments they could provide a hypoxic environment that benefited 
tumor metastasis and thus showed increased spread to the lungs. Furthermore, the human 
cancer cell line MDA-MB-231 has also been shown to be capable of growth in the kidneys if 
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it is injected in the renal capsule. In this model they were additionally able to show that the 
MDA-MB-231 cells could invade from the renal capsule into the cortex of the kidney (Liu 
2007). 
 The evidence for both Paget’s seed-and-soil and Ewing’s vasculature hypothesis are 
numerous from both sides. Research has shown that tumors do indeed have a propensity to 
spread to and grow in specific organs, while additional research shows that by by-passing 
the endothelial barrier by forcing vascular leakage or direct injection to parenchyma allows 
for non-organotropic growth. Rather than a one or the other argument, much like nature 
versus nurture, both hypothesis are likely correct. However, rather than an effect on the 
parenchymal space as argued by the existence of the pre-metastatic niche, it is the effect 
that a primary tumor has on the organ specific vasculature that may determine metastatic 
organotropism.  
 Vascular System  
From the microbiological standpoint research into vascular biology has yielded 
interesting developments since its description as the cardiovascular system by Hippocrates. 
The endothelium is the inner most layer of the vascular tubing that makes up the circulatory 
system. This one cell layer thick barrier separates the luminal side of the hematopoietic 
system from the parenchymal space of organs, the abluminal perivascular side. While the 
luminal side is always exposed to the rapid flow of the circulatory system the abluminal side 
has profound differences depending on whether it is found in an artery, arteriole, metartiole, 
capillary, venules, or vein. The layers of the vasculature consist of three layers, the tunica 
intima (the innermost endothetial layer), the tunica media and the tunica adventia, the 
outermost layer which connects the vessels to the surrounding tissue (Grey 2005, 
Junqueira 2010).  
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Arteries: Branching out from the heart these arteries are large elastic arteries. These 
have an tunica intima similar to other aspects of the circulation. The tunica media consists 
of thick layer called the internal elastic lamina that can stretch under the high pressures 
found in the large arteries. The media of the arteries is the most distinguishing feature due 
to its thickness and layers of smooth muscle fibers. The adventia is thinner than the media, 
but contains immune cells, nerves and the vaso vorum (the vessel capillaries). These 
branch into the muscular arteries which begin the distribution of blood to the organs (Grey 
2005, Junqueira 2010).  
Arterioloes: The muscular arteries repeatedly begin branching off into smaller and 
smaller arterioles. Arterioles have a much smaller tunica media with only two smooth 
muscle layers as compared to the 40-50 layers in the arteries. In this layer there is almost 
no visible adventia layer. The arterioles denote the beginning of organ vasculature (Grey 
2005, Junqueira 2010). 
Capillaries: It is at the stage of the capillaries that the majority of nutrient and gas 
exchange occurs with the surrounding organ in capillary beds. Capillaries have a single 
endothelial layer forming the vascular tube, and being only one cell thick they allow only 
single cell luminal transport at a time. They no longer have a smooth muscle layer. While 
they are the smallest of the vessels they are almost the most numerous, making up 90% of 
the vasculature (Figure 3) (Grey 2005, Junqueira 2010). 
It is important to note that capillaries differ significantly in number and type based on 
which organ they are found. Three different types of capillaries exist:  
1) Continuous: These have no junctional spaces between endothelial cells and are 
marked by well-defined tight junctions. They are the most numerous type of 
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capillary and are found in muscle, lungs and exocrine glands. Their tight-
junctions allow for the highly regulated transport of molecules across the vascular 
barrier (Grey 2005, Junqueira 2010).  
2) Fenestrated: The second type of capillary has what is described as a sieve-like 
structure. These have many small openings along the endothelium allowing for 
the transport of larger more extensive molecules. One would expect to find these 
in organs that require rapid transport of multiple macro-molecules across the 
vascular barrier such as the bodies filter, the kidney, food absorption in the 
intestine and endocrine glands (Grey 2005, Junqueira 2010). 
3) Discontinuous: Sinusoidal capillaries have large openings between endothelial 
cells allowing for maximum exchange of molecules across the vascular barrier. 
This discontinuous layer also allows for cells to cross the vascular barrier with 
more ease than other capillaries and can thus be found in the liver and spleen 
predominantly (Grey 2005, Junqueira 2010).  
 
Figure 3: Schematic representation of A) continuous B) fenestrated and C) sinusoidal capillaries. 
(Junqueira, L. C. U. a., J. Carneiro and A. N. Contopoulos Basic histology. A Concise medical 
library for practitioner and student. Los Altos, Calif). Copyright Clearance 11611970. 
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Pericytes: In addition to differences in types of capillaries, there is also a marked 
variation in the coverage of pericytes in differing organ capillary vasculature. 
Pericytes are a mesenchymal cell that wraps around the capillaries with foot 
processes (Figure 4). They have been implicated in vessel stability, involvement 
in contractile functions of the vasculature and have been shown to communicate 
directly with the endothelial cells to which they are attached (Armulik 2011). 
Through electron microscopy, immunofluorescence and histology percicytes 
have been shown to wrap around endothelial cell capillaries at varying intervals 
depending on the organ observed. In the retina the ratio of pericyte to endothelial 
cell is close to 1:1, while in other tissues it may be closer to 10:1 and has yet to 
be characterized for all organs (Armulik 2011). Thus, to date there has been no 
extensive characterization of pericyte coverage comparison between each organ. 
By reviewing publications that have used healthy controls of either kidney or 
lungs stained with NG2, PDGFRb or Desmin it is evident that the kidney cortex 
pericyte coverage is less than that of the pericyte coverage in the lungs (Armulik 
2011). Regardless, this is an insufficient methods of analysis and an in depth 
characterization of organ specific pericyte coverage is required.  
Pericytes share a basement membrane with the endothelial cell on which 
they are found and connect to the endothelial cell via an adhesion plaque and 
peg-and-socket joints. The adhesion plaque consists primarily of fibronectin and 
structurally resembles adherence junctions. The peg-and-socket joint on the 
other hand has shown evidence of gap junctions (Armulik 2011). Particularly the 
Connexin 43 gap junction has been shown to allow for communication between 
endothelial cells and pericytes (Winkler 2011).  
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While pericytes where first identified in 1873 by Dr. Charles-Marie Benjamin 
Rouget, research into their roles and function in normal physiology and pathology 
has been limited to a select few researchers (Armulik 2011). One key issue with 
pericyte research has revolved around a lack of unilateral agreement of 
identifying markers. Currently the markers that have been validated for pericytes 
are PDGFRb, NG2, CD13, aSMA, and desmin (Figure 5). PDGFRb and NG2 
markers appear to be associated with pericyte recruitment to vasculature and 
thus would seem to represent a possibly more immature stage of pericyte 
(Armulik 2011). In contrast, Desmin, which is a contractile filament predominantly 
expressed in the heart and muscle is a marker for mature pericytes and lends to 
the generally accepted view that pericytes are involved in vascular constriction 
and relaxation. It is important to note that in addition to being positive for the 
following markers pericytes are also identified by their proximity to vessels. While 
this can be done using an electron microscope, co-immunofluorescent staining is 
necessary to show both pericyte markers and endothelial cells (Armulik 2011).  
Figure 4:  The Structural and Molecular Connections between Pericytes and Endothelial 
cells. (Winkler, E. A., R. D. Bell and B. V. Zlokovic (2011). "Central nervous system 
pericytes in health and disease." Nat Neurosci 14(11): 1398-1405). Pericytes connect to 
endothelial cells by Adhesion plaques and Peg-and-Socket joints. Right provided by 
Nature Publishing group.  
4007140417745 
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More recent research from Dr. Raghu Kalluri and Dr. Valerie LeBleu has 
highlighted the role of pericytes in pathological states. The 2015 paper by Keskin 
et al. showed the role of pericytes at different stages of tumor development by 
selectively ablating proliferating pericytes at either early or late stage of tumor 
development in a mouse model of breast cancer. In 2013 LeBleu et al. used 
genetically engineered mouse models to fate map the source of myofibroblasts in 
kidney fibrosis. She noted that the majority of myofibroblasts that contribute to 
excess collagen in fibrosis are derived from local fibroblasts that differentiate into 
myofibroblasts when exposed to certain cytokines. The remaining myofibroblasts 
where derived from the bone marrow, endothelial cells undergoing EndMT and 
epithelial cells undergoing EMT. However, they found that NG2 and PDGFb 
pericytes while increasing during kidney fibrosis did not contribute to the 
myofibroblast population within kidney fibrosis. 
Figure 5:  Pericyte markers in murine research. PDGFRb, NG2, CD13, aSMA, and Desmin have all 
been validated as murine markers of perciytes when associated with vasculature (Armulik, A., G. 
Genove and C. Betsholtz (2011). "Pericytes: developmental, physiological, and pathological 
perspectives, problems, and promises." Dev Cell 21(2): 193-215). Elsevier user license CC BY 4.0. 
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The role of pericytes in lung fibrosis has also been characterized using similar 
methodologies. In 2013 Hung et al. used Foxd1 tagged to Tomato red to show 
that this population overlapped with PDGFRb positive cells and was thus a 
pericyte population. Utilizing Bleomycin to induce lung fibrosis they showed that 
this population contributed significantly to the fibrotic environment. However, in 
2013 Rock et al. used NG2 expressing GFP under the control of Tamoxifen 
inducible promoter to map the expression of pericytes during bleomycin induced 
lung fibrosis. While they noted an increase in NG2 and PDGFRb positive cells in 
lung fibrosis they did not see a costaining with aSMA, which would indicate the 
transition from pericyte to myofibroblast. These conflicting reports underline the 
issue of the need for agreement on pericyte identification.  
Venules: After leaving the capillaries the circulation travels to the venules which also 
have pericyte coverage. In post-capillary venules it has been found that these are the 
primary sites that white blood cells diapedesis to parenchymal tissue during the 
inflammatory process. The observation that white blood cells diapedesis specifically at 
venules is of importance as it highlights the heterogeneity of endothelial cells. As the 
venules increase in size towards veins, they show an ever increasing tunica media with 
smooth muscle layers. A key characteristic of venules is they have a lumen that is far wider 
in diameter than the thickness of their wall (Grey 2005, Junqueira 2010). 
Veins: Unlike arteries veins have a relatively low pressure and thus move blood flow 
back to the heart via the contraction of large smooth muscle around the vessel. This 
function leads to the structural characteristic that veins have a prominent intima, a small 
media and an adventia with large smooth muscle fibers for contraction (Grey 2005, 
Junqueira 2010). 
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 The description of the vascular system highlights that most circulating tumor cell 
extravasation occurs in capillaries responsible for organ oxygenation and nutrient supply. Of 
interesting note is that despite the different capillary types this does not seem to correlate 
with organotropism. For example, lungs have continuous endothelial capillaries whereas 
kidneys are known to have fenestrated capillary endothelium. Given the presence of the 
small holes and macromolecules crossing the endothelial border it would stand to reason 
that the kidney should be a site of metastatic spread. However, as is apparent from Figure 
2. the kidney is not a common site of metastatic spread in any primary tumor.  
 In addition to the endothelium of the lungs being continuous and that of the kidneys 
being fenestrated both have unique vascular structure, but are highly vascularized. Blood 
flow to the kidney enters via the renal artery at the hilus, flows into the interlobar artery, the 
arcuate artery, the interlobular artery, then efferent arteriole of the glomerulus (Figure 6A) 
and into the capillary tuft that forms the glomerulus (Figure 6B). From here blood flows out 
of the glomerular tuft via the efferent arteriole and into either peritubular capillaries or the 
vasa recta capillaries depending on the cortical location of the glomerulus. The peritubular 
capillaries and vasa recta are the capillary structure of the kidney and ensure the cortex and 
medulla of the kidney are highly vascularized as this is where water, Na2+, Cl- and other 
ions are reabsorbed (Figure 6C). Blood then leaves the kidneys via veins with the same 
names as the capillaries and arteries (Grey 2005, Junqueira 2010). The glomerular tuft is a 
unique structure in that the capillaries in this structure are covered by a specialized cell 
called a podocyte. Podocytes, similar to pericytes form foot processes around the 
capillaries. These foot processes interdigit and form a filtration slit diaphragm, therefore in 
addition to having to cross the endothelial layer, molecules and or cells also have to cross 
the filtration slit diaphragm in order to enter the parenchymal space of the kidney. Research 
21 
 
has shown that in some pathologies such as Alport syndrome red blood cells can cross the 
endothelial layer in the glomerular tuft and enter the filtrate. Of interest is recent research 
showing that the under other pathological conditions the slit-diaphragm can in fact tighten 
with the increased expression of Claudin-1 between pedicel processes. This increased 
expression of Claudin-1 would generate tight junctions that are less permeable to molecules 
crossing the glomerular basement membrane barrier. However, upon leaving the efferent 
arteriole only a single layer of capillary endothelial cells separates the circulation from the 
parenchymal space in the peritubular arteries and the vasa recata. Finally, the hydrostatic 
and osmotic pressure within the kidney is highly unique due to its filtration function. As the 
glomerulus filters out ions but is not permeable to larger molecules such as Albumin there is 
an increase in protein concentration within the plasma circulating in the kidneys. This 
increases as water is absorbed by the proximal tubules and further ions are absorbed by 
the tubules further along the nephron. Thus typical pressures in the vasculature of the 
kidney are 20-30mmHg starting at the glomerulus and increasing as more ions are 
transported out and the protein to plasma concentration increases (Grey 2005, Junqueira 
2010).  
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Relative to the kidney, the pressures in the lung are much lower ranging from 5-
25mmHg (Grey 2005, Junqueira 2010). This allows the pulmonary vessels to be thin 
allotting to the function of the lungs of transport of Oxygen and Carbon Dioxide within the 
Figure 6:  Vasculature and blood of the kidney. A) The 
Glomerular tuft consists of capillaries surrounded by 
podocytes that form the filtration slit diaphragm. B) Kidney 
blood flow route. C) The peritubular capillaries and vasa 
recta capillaries surround the kidney nephron for reuptake 
of solutes and water (Junqueira, L. C. U. a., J. Carneiro 
and A. N. Contopoulos Basic histology. A Concise medical 
library for practitioner and student. Los Altos, Calif). 
Copyright Clearance 11611970. 
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alveolar ducts. The alveolar ducts are made up of alveoli that are capable of diffusing O2 
and CO2 with blood in the surround capillary network (Figure 7). Blood leaves the left 
ventricle of the heart and enters the lungs through the pulmonary artery where it branches 
into capillaries that line the alveoli. Once reoxygenated the blood then returns to the heart 
via the pulmonary vein and is ultimately pumped to the systemic circulation by the aorta 
(Grey 2005, Junqueira 2010). 
 
 
 
 
 
 
 
Figure 7:  Vasculature of the Lung. Pulmonary capillaries allow for the diffusion of O2 and CO2. Type 
I cells are primarily responsible for the gas diffusion. Type II cells are primarily responsible for the 
production of surfactant to lubricate the lungs and prevent larger macromolecules crossing into 
perivascular spaces. (Junqueira, L. C. U. a., J. Carneiro and A. N. Contopoulos Basic histology. A 
Concise medical library for practitioner and student. Los Altos, Calif). Copyright Clearance 
11611970. 
  
  
 
 
 
 
 
 
 
 
24 
 
Angiogenesis and Angiopoietins 
In 1779 surgeon Dr. John Hunter stated whenever “Nature has considerable 
operations going on, and those are rapid, then we find the vascular system in a 
proportionable degree enlarged (Eiseman 1984).” This observation was likely the first 
description of the changes that the vascular system undergoes in both normal healthy 
physiology beginning in utero and under many pathological conditions as well. The term 
angiogenesis was coined first during the description of the formation of the placenta (Hertig 
1935). However, it was not until 1971 when Dr. Judah Folkman published his work 
describing the angiogenic process in tumor growth and cancer dependence on 
angiogenesis that the importance of the angiogenic process became evident in both normal 
and pathological conditions (Folkman 1971).  
Vasculogenesis begins in utero and is the first aspect of embryo development 
beginning after gastrulation to ensure the formation of the cardiovascular system. This 
differs from angiogenesis in that it is the de novo formation of vessels from the mesoderm. It 
can also occur post utero with the development of new vessels from angioblasts. 
Angiogenesis on the other hand is the formation of blood vessels from existing vessels and 
can occur via two differing mechanisms (Figure 8) (Hunt 2002):  
1) Sprouting Growth: Sprouting angiogenesis occurs with the formation of a tip cell 
from an existing capillary or vessel. This requires that surrounding basement 
membrane be proteloytically degraded, that endothelial cells migrate and 
proliferate, and ultimately that they are finally stabilized by mature pericytes. The 
tip cell begins the process by budding off from the parent vessel and moving 
towards the direction of a pro-angiogenic factor (such as VEGF). By utilizing 
filapodia tip cells are able to degrade surrounding basement membrane and 
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extracellular matrix to allow for the growth of vessels. Once the tip cell has 
reached another vessel they anastomize and become a connected capillary with 
a fully formed lumen. At this point pericytes will cover the endothelial cells and 
ensure stabilization.  
2) Inteussceptive Growth: In contrast to Sprouting angiogenesis, this process 
involves the splitting of the vessels and lumen into two vessels. This was first 
observed in the lung and is believed to be a more rapid form of angiogenesis.  
 
 
 
 
 
 
 
 
 
 
Both forms of angiogenesis require either mechanical or growth factor stimulus to 
begin the process of vessel growth. Evidence suggests that angiogenesis is a balance 
process in that vessels are generally quiescent when there is a balance between pro-
angiogenic factors and anti-angiogenic factors (Hunt 2002). Upon stimulation by either 
mechanical means or by growth factors the scales can be tipped in one direction to initiate 
Figure 8:  The three methods of angiogenetic growth A) Classical capillary growth B) 
Intussusceptive growth C) Longitudinal growth (Hunter, J. (2007). "A treatise on the blood, 
inflammation, and gun-shot wounds. 1794." Clin Orthop Relat Res 458: 27-34). 
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the angiogenic process. Mechanistically anything from cold, changes in blood flow pressure, 
and shear stress can initiate angiogenesis. The presence of hypoxia in tissues is a key 
initiator for angiogenesis (Hunt 2002).  For example, exercise has been shown to initiate 
angiogenesis in the heart and muscles, while excess adipose tissue development has 
shown an increase in angiogenesis as well (Hunt 2002). While exercise is beneficial and 
excess adipose tissue growth is considered non-beneficial this highlights the role of 
angiogenesis in both normal and pathological processes. Angiogenesis is key in normal 
wound healing, but is implicated in tumor growth and many other pathologies.  
In association with the mechanical stimulus there are also a number of growth 
factors that have been shown to be pro-angiogenic and anti-angiogenic (Figure 9). As 
previously mentioned hypoxia is well established to induce the angiogenic process, and this 
occurs when epithelial and stromal cells begin secreting pro-angiogentic factors in response 
to hypoxia so as to ensure vessel growth to increase vascularization of that hypoxic area 
(Hunt 2002).  
 
 
 
 
 
  
 
 
Figure 9:  Factors affecting angiogenesis as determined from in vitro 
studies(Hunter, J. (2007). "A treatise on the blood, inflammation, and gun-
shot wounds. 1794." Clin Orthop Relat Res 458: 27-34). 
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VEGF is considered a key indispensable growth factor for angiogenesis, but 
nonetheless there are significant other factors that are involved in initiating and maintaining 
the angiogenic process (Hunt 2002). The angiopoietins are an interesting angiogenic growth 
factor as they come in multiple isoforms which work antagonistically to ensure a balance of 
pro and anti angiogenic factors.  
 The tyrosine kinase receptor Tie-2 has been shown to be expressed predominantly 
on endothelial cells and given that it has been shown through xray-crystalography studies 
that both Angiopoietin 1 and Angiopoietin 2 are highly specific ligands for Tie-2 extensive 
research has been focused on the effects of these angiopoietins on the vascular system 
(Barton 2006). Significant research has shown that these two ligands act antithetically on 
endothelial cells; Angiopoietin 1 stabilizes endothelial cell-cell interactions and limits 
vascular permeability, Angiopoietin 2 has the opposite effect and decreases the endothelial 
cell-cell interaction and leads to increased vascular leakage (Fagiani 2013). In combination 
with increased levels of VEGF, Angiopoietin 2 has been shown to promote the angiogenic 
process. While this may prove beneficial in normal healthy regulated physiology such as 
wounds, in the pathological circumstances when excess Angiopoietin 2 is created this can 
lead to systemic vascular leakage (Parikh 2006). In fact, excess expression of Angiopoietin 
2 has been linked with poor prognosis for breast cancer patient metastatic disease (Keskin 
and Kalluri 2015).  
 The angiopoietins work by binding to Tie-2 on endothelial cells and causing 
intracellular downstream alterations that lead to either the stabilization or destabilization of 
tight and adherent junctions between cells (Figure 10A, B). Angiopoietin 2, on binding to 
Tie-2 increases the intracellular cytoplasmic levels of Rac to RhoA ratio, which in turn is 
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believed to destabilize both tight junction complexes and adherent junction complexes 
(Felcht 2012).  
 
 
 
 
 
 
  
The antagonistic nature of the angiopoietins has led to research showing that under normal 
physiological conditions the ratio of Angiopoietin 1 to Angiopoietin 2 shows higher levels of 
the former. Conversely, when tissue damage occurs there is a rapid release of Angiopoietin 
2. This occurs as Angiopoietin 2, with a half-life of 18 hours is stored in Weibell-Palade 
bodies, which are small organelles found in endothelial cells (Rondaij 2006). Weibell-Palade 
bodies were initially studied for their storage properties of Von Willibrand factor, a 
fundamental clotting factor responsible for platelet binding during tissue damage. Later 
research found that Angiopoietin 2 is also stored in Weibelle-Palade bodies and rapidly 
released to tip that balance towards the pro-angiogenic process so as to re-vascularize 
damaged tissue (Valentijn 2011). More recent research has shown that Weibelle-Palade 
bodies are in fact a heterogeneous population in that some have Angiopoietin 2 stored, 
while others seem to store P-selectin in an exclusive manner (Valentijn 2011). Lending 
further evidence to the argument that vasculature in different organs may in fact respond 
Figure 10: A) Representation of Tie 2 receptor and Angiopoietin structure. B) Representation of 
Angiopoietin binding to Tie 2 (Fagiani, E. and G. Christofori (2013). "Angiopoietins in angiogenesis." 
Cancer Lett 328(1): 18-26). Elsevier user license CC BY 4.0. 
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differently to the same stimulus. In fact, on comparison of quiescent lung and kidney 
endothelium it has been found that significantly higher levels of Angiopoietin 2 are 
expressed in the kidneys (Gale and Yancopoulos 2002). This indicates that the kidneys 
store Angiopoietin 2 in Weibell -Palade bodies at higher levels than the lungs.  
Tight Junctions 
Tight Junctions are the most apically located junctions that are responsible for cell-
cell contact and can be found in epithelial and endothelial tissues (Figure 12B) (Steed 
2010). Typically, fibroblasts have been shown to not express tight junction proteins. Due to 
the apical location of tight junctions in the endothelial cells they are key structures involved 
in the regulation of vascular permeability (Anderson 2009). This is predominantly true for 
large structures crossing the endothelial barrier such as immune cells or circulating tumor 
cells. Whereas smaller molecules may be transported through endothelial cells via a 
process known as transcellular transendothelial migration, larger structures such as cells 
have been shown to almost exclusively cross by paracellular transendothelial migration 
which is by passing between two endothelial cells (Erika 2009). In the presence of complete 
tight junction complexes between endothelial cells there is a limited capability for cells or 
larger macromolecules to cross the endothelial barrier (Figure 11). However, as mentioned 
above when there is increased expression of pro-angiogentic growth factors such as VEGF 
and Angiopoietin 2, the proteins of tight junction complexes become dissociated leading to 
increase vascular permeability.  
 
 
 
1. Figure 11: A) Electron Microscope Image of endothelial cells tight junction. B) Schematic 
representation of transmembrane proteins responsible for tight junction formation. (Weiss, 
N., F. Miller, S. Cazaubon and P. O. Couraud (2009). "The blood-brain barrier in brain 
homeostasis and neurological diseases." Biochim Biophys Acta 1788(4): 842-857). Elsevier 
user license CC BY 4.0. 
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Tight junction complexes consist of multiple proteins bound together to form the 
connection between two cells. The three transmembrane proteins directly responsible for 
cell-cell binding are the claudins, occludin and the junction adhesion molecules (Steed 
2010). Knock out experiments have shown that occludin is not required to form the tight 
junction, but is involved in recruitment of the proteins to the tight junction complex (Yu 
2005). There are three junction adhesion molecules (Jam1,2,3) that have also been shown 
to be involved in stabilization of tight junctions and their knockout has led to increased 
sensitivity to inflammation (Anderson 2009). The claudin family of proteins, of which there 
are 27 isoforms in mus musculus (Ouban 2012), are the primary proteins that form tight 
junctions. Research has shown that there are two types of claudins, tight junction forming 
and channel forming. The tight junction forming claudins are responsible for the binding of 
cells to adjacent cells and barrier function, while the channel forming claudins form 
communication pores between adjacent cells, similarly to the gap junction connexins 
(Krause 2008). Claudins have been shown to bind to claudins on adjacent cells, and 
although every combination and permutation has not been tested it does appear that 
claudins can bind to like claudins and some can also bind to different isoforms (Anderson 
2009.  
 
 
 
 
 
Figure 12: A) Representation of transmembrane proteins interactions and binding to proteins of the 
Tight Junction complex. B) Image depicting the apical localization of the tight junctions in both 
epithelial and endothelial cells. C) Schematic of ZO-1 binding sites. (Bazzoni, G. and E. Dejana 
(2004). "Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis." 
Physiol Rev 84(3): 869-901). Permission is not required for this type of use. 
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To localize to and stabilize tight junctions as transmembrane proteins the claudins, 
occludin and the JAMs intracellular domains bind to the Zonnula Occludin 1 (ZO-1) protein 
on specific domains (Figure 12A) (Bazzoni 2004). The claudins have been shown to bind 
to the PDZ1 domain, the JAMs to the PDZ2 and PDZ3 and occludin binds to the GuK 
domain (Bazzoni 2004). There is an additional SH3 domain that has been shown to be 
necessary for PDZ binding stabilization (Lye 2010). Upon dissociation of the 
transmembrane proteins from ZO-1, the ZO-1 protein delocalizes from the membrane and 
moves towards the nucleus, although it’s function at and near the nucleus is not known 
(Figure 12C) (Bauer 2010). In fact, it has been shown that during the process of EMT there 
is a decrease in membrane ZO-1 as the tumorigenic cells gain the ability to survive without 
cell-cell contacts (Zeisberg 2009).  
Unfortunately, there has been limited research on the tight junctions that exist 
between endothelial cells within different tissues and organs. The majority of tight junction 
research has focused on epithelial cells and is inferred to endothelial cells. For example, it 
has been shown that different claudins predominant at different stages along the epithelial 
Figure 13: Representation of the location of the Claudin tight junction proteins along the kidney 
nephron. (4. Angelow, S., R. Ahlstrom and A. S. Yu (2008). "Biology of claudins." Am J Physiol 
Renal Physiol 295(4): F867-876). Permission is not required for this type of use. 
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cells of the kidney nephron (Figure 13) and that there is a kidney specific Claudin-10a that 
is also expressed between vasa recta of the kidney (Angelow 2008). Additionally, at least 
within the kidney it appears that there exist two isoforms of the ZO-1 protein, being either 
positive or negative for an 80 amino acid alpha motif (Anderson 1993). While the epithelial 
cells and parietal cells of the Bowman’s capsule express the α+ isoform the slit-diaphragm 
and endothelial cells to express the α isoform.  
A search of the literature found two papers in which they also show that the α 
isoform is expressed in the endothelium of the lung as well.  However, research into the 
specific endothelial tight junction complex appears to be limited. The research that has been 
done into the endothelial tight junctions has identified Claudin-5 as a key component of 
vascular tight junctions (Escudero-Esparza 2011). Claudin-5 has been shown to be 
dysregulated in gliomas (Karnati 2014), in the blood-brain barrier in brain metastasis 
(Avraham 2014), and in lung pathologies such as acute lung injury leading to pulmonary 
edema (Chen 2013). It has also been shown to be found in the endothelial cells of the 
kidneys (Morita 1999). A 2014 study by Camire et al showed that when brain endothelial 
cells are treated with 3-chloropropanediol there is a loss of tight junctions (Camire 2014). 
Using a time course post-treatment, they showed that Claudin-5 expression goes down 90 
minutes after exposure, but returns to normal levels after 120 minutes. By using PI3K and 
AKT inhibitors they determined that the PI3K pathway is predominantly responsible for 
Claudin-5 expression in brain endothelial cells. These findings implicate Claudin-5 as a key 
regulator of vascular permeability in multiple organs.  
While significantly more characterization of the differences in endothelial tight 
junctions is required between each organ, there does appear to be organ specific 
endothelial tight junction complexes regulating organ vasculature.  
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 Wound Healing, Cancer and Fibrosis 
 In 1986, the researcher credited with the discovery of VEGF, Dr. Harold Fisher 
Dvorak wrote that “tumors are wounds that do not heal” (Dvorak 2015). The 
histopathological similarities between tumors and the wound healing process led him to this 
statement that has been used ever since. Since this declaration significant biochemical, 
biophysical and histological research has indeed shown that wound healing, pathological 
wound healing (fibrosis), and tumorigenesis have significant similarities (Arwert 2012). 
 The wound healing process is a well-characterized process that can be broken down 
into four overlapping phases that begin at differing times post tissue insult. The process 
begins with hemostasis and inflammation in which the body ensures the prevention of blood 
loss through the secretion of clotting factors such as Von Willibrand factor, and the 
recruitment of immune cells to the location of damage which are the first two steps. The 
third phase is marked by proliferation with increased angiogenesis to revascularize the 
wounded area and an increase in myofibroblasts to close the wound. The final stage is 
called granulation in which the deposition and cross-linking of collagen to replace the 
functional epithelial tissue that was damaged by the insult occurs (Gurtner 2008). The 
deposited collagen tissue cannot perform the function of the epithelial tissue that it replaces 
and acts like a scaffold as opposed to performing a parenchymal role. This would be akin to 
an elevator being replaced by building rebar, the elevator no longer works but the building 
stays standing. It is for this reason that skin scars do not grow hair, sweat or tan and is thus 
the prime cause of thermodysregulation in patients with significant skin burns as their 
epithelial tissue that was responsible for thermoregulation has been destroyed and replaced 
with non-functional scar tissue (Church 2006). In the normal wound healing process this 
process is self-regulating and once revascularization and granulation have occurred the 
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pro-wound healing factors are downregulated and the process resolves (Gurtner 2008). In 
the case of fibrosis and tumorigenesis these factors are constitutively upregulated and 
overexpressed leading to a self-perpetuating wound healing process and thus the excess 
deposition of collagen tissue, continued angiogenesis, and the destruction of surrounding 
functional parenchymal tissue. When this occurs in a vital organ, if left unchecked can lead 
to organ failure and death. 
 Given that the varying stages of wound healing involve angiogenesis and the 
proliferation of myofibroblasts, the similarities between fibrosis and tumorigenesis become 
evident (Figure 14A) (Arwert 2012). It is the kinetics that makes the key difference between 
healthy wound healing and pathological fibrosis and tumorigenesis. A 2001 paper by 
Kampfer et al characterized the mRNA expression levels of skin Angiopoietin 1 and 
Angiopoietin 2 in mice with cutaneous wounds and found that after initial injury the levels 
increased, but rapidly declined to basal levels after day 7. Conversely in mouse models of 
diabetes the skin mRNA levels of Angiopoietin 2 did not resolve after day 7 (Kämpfer 2001). 
Fibrosis research has shown that due to the presence of fibrotic tissue in patients with liver 
cirrhosis, chronic gastritis, and other fibrotic disorders predisposes them to the development 
of cancer in the afflicted organ. For example, liver cirrhosis is a significant risk factor for 
hepatocellular carcinoma (Bugianesi 2002). Thus the presence of excess wound healing 
factors promotes the development of tumor growth (Figure 14B, Figure 15).  
 Numerous studies focusing on individual factors increased in the fibrotic environment 
have shown their pro-tumorigenic properties. A prime example of this is Lysyl Oxidase 
(LOX) and its significant increase during fibrosis. Increase LOX during fibrosis occurs as it is 
involved in and necessary for proper cross-linking of newly developed collagen fibers. Dr. 
Janine Erlner published works showing in Bleomycin induced fibrotic lungs and Carbon 
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Tetrachloride induced fibrotic livers there was increased metastatic spread from 4T1 cells to 
those fibrotic organs as compared to their non-fibrotic controls (Cox 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: A) Diagrammatic comparison between the wound healing process and the process of 
tumor growth and invasion. B) A Comparison between wound healing and cancer. (Arwert, E. N., E. 
Hoste and F. M. Watt (2012). "Epithelial stem cells, wound healing and cancer." Nat Rev Cancer 
12(3): 170-180). Right provided by Nature Publishing group.  
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Furthermore, they showed that high levels of secreted LOX from primary tumors alters the 
environment of organotropic organs such as the bone to develop a pre-metastatic niche 
(Cox 2016). They also found that secreted LOX binds to fibronectin in the lungs as similar to 
their bone findings prepares the lungs soil for seeding from the primary tumor. LOX is one 
of many pro-tumorigenic factors that have been published showing similarities between the 
fibrotic environment and the tumor microenvironment (Cox 2016). 
 
  
 
 
  
 
 
 
 
 
 
Summary 
  
Figure 15: Table showing the cytokines implicated in both wound healing and in the cancer growth 
and development. (Arwert, E. N., E. Hoste and F. M. Watt (2012). "Epithelial stem cells, wound 
healing and cancer." Nat Rev Cancer 12(3): 170-180). Right provided by Nature Publishing group.  
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Despite the fact that metastasis is the primary cause of mortality in patients with a 
cancer diagnosis, there are limited therapies to treat metastatic disease. Even armed with 
the knowledge of where specific tumors are likely to spread to we still have limited 
knowledge about the etiology of organotropism and why certain organs are more 
susceptible to metastatic spread over others, for example why are the lungs a common site 
of metastasis while the kidney is rarely ever found to have metastatic disease. Both are 
major sites of blood flow, have significant capillary coverage, high perfusion rates and 
require the diffusion of macromolecules across the endothelial barrier for function. 
Furthermore, direct injection to bypass the endothelial barrier or mechanical manipulation of 
systemic vasculature has shown that cancer cells can grow in non-organotropic 
parenchyma if able to reach that environment. This clearly indicates that if cancer cells are 
able to cross the endothelial barrier that they will likely able to grow in the parenchymal 
space of whatever organ they disseminated to. This appears to be a contradiction to 
Paget’s generally accepted seed-and-soil hypothesis.  
 Rather than seemingly contradicting Paget or Ewing’s hypothesis, an amalgamation 
of the two theories might help to explain metastatic organotropism. The vascular system is 
not a homogenous system, and it is clear that the vasculature of different organs is not only 
physically different but may also respond differently to the same secreting cytokines. This 
would indicate that metastatic organotropism is likely due at least in part to the 
heterogeneous nature of organ specific vasculature and its response to circulating pro-
tumorigenic factors.  
Such pro-tumorigenic factors can be found in the wound healing process, but are 
found both in excess and for chronically longer durations post insult during fibrosis, 
tumorigenesis and other pathological states. During these pathological states these factors 
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are secreted into the circulation and will thus have systemic effects. Cytokines once in 
circulation will make direct contact with the luminal side of the endothelium prior to any 
other cell type. Given that these cytokines are pro-angiogenic and are by all essential 
reasoning bombarding the endothelium, one would expect there to be wide ranging 
systemic organ damage in any disease which leads to excess circulating fibrotic or 
tumorigenic factors. However, that is not the case. For example, in patients with Sepsis, 
who have increased levels of circulating Angiopoietin 2, TNFa and TGFb, all factors 
associated with pro-fibrosis and pro-tumor growth, the lungs are predominantly effected 
leading to an increase in pulmonary edema due to vascular leakage. While some other 
organs are also affected, not every organ appears to have vascular alterations in these 
circumstances leading to further evidence that the endothelial responses to cytokines are 
organ specific.  
 Here we hypothesize that organ specific vasculature responds differently to the 
same cytokines in circulation. Thus in the presence of tumor or fibrosis secreted cytokines 
only certain organs would show altered vasculature that increases their vascular 
permeability and increases the likelihood of paracellular transendothelial migration of 
circulating tumor cells. By inducing fibrosis in both organotropic lungs and non-organtropic 
kidneys in mouse models of breast cancer we can determine whether the pro-tumorigenic 
fibrotic environment is capable of redirecting metastasis to a non-tropic organ. Furthermore, 
this allows us to determine the differential organ specific vascular response of excess 
secreted cytokines from fibrosis or tumors.  
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Chapter 2 Material and Methods 
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Anesthesia: Mice will be anesthetized with Ketamine/Xylazine (Ketamine (100mg/kg body 
weight); Xylazine (10g/kg body weight)). The duration of the anesthesia is 30-60minutes.  
Analgesia: Bupreorphine will be given subcutaneously (0.1mg/kgBW in 100ul PBS) prior to 
skin incision, then at 12 and 24 hours after operation.  
Wound Induction: The wound induction is a unilateral 8mm dorsal wound that resolves in 
10-17 days. The right dorsal aspect of the mice will be shaved and the skin prepped with 
betadine and alcohol. Approximately 1cm right from the dorsal central axis of the mouse a 
Miltex 8mm Sterile Disposable Biopsy Punch will be used to remove the dermal layer down 
to the peritoneum, without interrupting the peritoneum. The wound will be carefully cleaned 
with iodine post surgery and the mouse monitored for signs of infection.  
Bleomycin: Intratracheal Bleomycin injections will be used to induce lung fibrosis. Place the 
mouse supine on a surgical board. Elevate the surgical board to at least a 45-degree angle 
so that the mouse’s head is elevated above its thorax. A 1 cm incision will be made 
vertically along the trachea ensuring clear visualization of the muscle layer. The 
Sternohyoid muscles will be gently displaced to reveal the trachea. Using fine tip tweezers, 
the tracheal peritoneal layer will be removed so as to visualize the tracheal cartilage rings. 
Using a 28-gauge needle 100ul of Bleomycin (15 units) will be injected between two 
cartilage rings. Confirmation of a successful injection will be visualized by a momentary 
pulmonary distress. Pulmonary distress should resolve within 5-10 seconds. The 
Sternoyhoid muscles will be replaced and the epidermal layer will be sutured with 
continuous non-absorbable sutures. The wound will be cleaned and the mice monitored.  
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UUO: UUO or unilateral ureteral obstruction (mild to severe fibrosis that does not resolve, 
the mice are euthanized at 10 days’ post UUO). One 1.5 cm long longitudinal incision will be 
made on the abdomen, approximately at 0.5cm left of the nipples on the left flank of the 
animal (starting at the level of the 4th set of nipples and continuing 1.5cm toward the head of 
the animal and will not exceed 1.5cm). The skin will be gently separated from the 
peritoneum to expose the peritoneum. A second incision will be made in the peritoneum, 
longitudinally starting at the level of the 4th nipple and continuing 1cm toward the head of 
the animal, not to exceed 1cm in total length. The abdominal cavity is now open and the 
organs gently moved to expose the ureter. The ureter is then ligated with non-absorbable 
nylon string at 0.5 cm below the kidney. The peritoneum is then sutured with simple 
interrupted absorbable sutures while the skin is sutured with simple interrupted non-
absorbable sutures or surgical staples. Control mice include sham operation, which consists 
of exposing the ureter and closing peritoneum and skin.  
Breast Pad/ Mammary Gland Injection: Bilateral incisions will be made on the abdomen of 
the mice without interrupting the peritoneum.  Each incision will begin towards the hind leg 
of the animal between the 4th and 5th sets of nipples and extend towards the head of the 
animal no more than 1.5 cm. The skin will then be gently separated from the body cavity in 
order to expose the breast pad/mammary fat glands that are situated on the underside of 
the skin. Tumor cells (500,000 cells/20ul PBS per breast pad) will be injected into each 
breast pad using a Hamilton syringe fitted with a 25G needle. The abdominal incision will be 
closed using either simple interrupted vicryl sutures with non-absorbable nylon string or 
surgical staples.  
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Retroorbital Injection: Cell injections will be in 100ul volume and 500,000 cells in PBS 
retroorbitally. 
Breast Pad/Mammary Gland Injection+No Surgery/Wound/Sham/UUO: Mice will be 
implanted with 4T1 breast cancer cells into the mammary fat pads. When the tumors reach 
500mm3, cohorts will receive 1) no treatment, 2) Wound Induction, 3) Sham surgery, 4) 
UUO surgery, 5) Sham+IgG, 6) UUO+IgG 7) Sham+anti- Angiopoietin 2, or 8) UUO+anti-
Angiopoietin-2. All Mice will be sacrificed 10 days following surgery including control mice.  
Retroorbital Injection+No Surgery/Wound/Sham/UUO: Mice will be retroorbitally injected 
with 4T1 breast cancer cells. On the same day the mice will be also receive 1) no treatment, 
2) Wound Induction, 3) Sham surgery, 4) or UUO surgery. All Mice will be sacrificed 10 
days following surgery including control mice. 
Retroorbital Injection+Recombinant Angiopoietin 2 Treatment: A cohort of mice will receive 
2 intraperitoneal injections of 100ug recombinant mouse Angiopoietin 2 (7186-AN-025). The 
first injection will be given at day –1; the second injection will be given at day 3. The control 
group will receive PBS only. The mice will be euthanized at day 10. An additional cohort will 
be retroorbitally injected with 500,000 cancer cells at Day 0. The mice will be euthanized at 
day 10.  
Mouse Monitoring: The mice will be euthanized 10 days post wound induction. The dermal 
wound will be monitored daily for infection and 10% weight loss together with significant 
decreased activity/reactivity will be used to determine whether mice require euthanasia 
before the 10-day sacrifice time point. Tumor bearing mice will be monitored daily, tumors 
measured, and tumors necrosis, 10% weight loss together with significant decreased 
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activity/reactivity will be used to determine whether mice require euthanasia before the 10-
day sacrifice time point. All mice be euthanized upon tumor size reaching 1500mm3. 
Tissue collection during euthanasia: 1 hour prior to euthanization mice will be injected with 
FITC-Dextran 70,000kD at 100 mg/ml (46945). Mice will be anesthetized with 
Ketamine/Xylazine and cervically dislocated after collection of whole blood.  
Retroorbital Whole Blood Collection: Utilizing a glass pipet, 10ul of heparin will be collected 
into the pipet. The tip of the glass pipet will be inserted into the medial canthus of the eye 
under the nictitating membrane. Light pressure will puncture the sinus membrane and blood 
will begin to flow into the glass pipet.  
Tissue Collection: Post cervical dislocation, the mouse will be secured to a dissection board 
so its abdomen is exposed, and sprayed lightly with 75% ethanol to wet the fur and skin to 
prevent contamination. Perform an incision 1cm above the central axis of the genitalia, then 
continuing towards the mouse’s head will expose the abdominal cavity and the rib cage. 
The femoral artery will be perforated to allow blood to flow. Using surgical scissors, the rib 
cage will be removed exposing the lungs and heart. A 10ml syringe with PBS and a 20-
gauge needle will be inserted into the left ventricle of the heart and gentle pressure will be 
placed on the syringe. Successful perfusion will be evident by clear PBS flowing from the 
femoral perforation, and paling of the liver, kidneys, and lungs.  
Formalin Fixed Paraffin Embed: All tissues for FFPE will be collected into tissue cassettes 
and placed in formalin jars. They will be processed overnight and embed in paraffin no more 
than 2 days later.  
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Snap Frozen Tissue: All snap frozen tissue will be immediately placed in a 1.5ml Eppendorf 
Tube and put into liquid nitrogen. All snap frozen samples will be stored at -80C.  
Lungs: The left lung lobe will be collected for FFPE. The right superior and inferior lobes will 
be collected for OCT. The middle and post-caval lobe will be snap frozen.  
Liver: The median lobe will be collected for FFPE.  
Kidney: The fibrotic and contralateral kidney will be removed and separated into anterior 
and posterior sections using a surgical blade. The anterior of each kidney will be collected 
for FFPE. The posterior kidney will be separated into apical and basilar sections. The apical 
section will be processed for OCT and the basilar will be snap frozen.  
Tumor: Tumors will be weighed upon resection. Tumors will be separated into anterior and 
posterior sections using a surgical blade. The anterior tumor will be collected for FFPE. The 
posterior tumor will be separated into proximal and distal sections. The proximal tumor will 
be processed for OCT. The distal tumor will be snap frozen. Sections of all remaining tissue 
will be collected for FFPE and snap frozen tissue.  
Angiopoietin 2 ELISA: Whole blood will be spun down at 1500rpm for 5 minutes at 4C. 
Serum will be transferred to another 1.5ml Eppendorf tube. Angiopoietin-2 ELISA will be 
performed on serum using Abcam Angiopoietin-2 Mouse ELISA kit (ab171335).  
Metastasis Analysis: At least 2 5um thick representative sections of the lungs from each 
mouse will be stained with H&E. These slides will be scanned using Panoramic 250 Flash 
II. Each slide will be analyzed for metastasis on Panoramic Viewer. Metastatic burden will 
be calculated by dividing the area of metastasis by the total area of the lung. Differential 
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analysis will performed using Prism. Statistical analysis will be a unpaired 1-Way Anova 
comparing the mean of each group to the mean of each other group at 95% confidence to 
determine statistical significance.  
Immunofluorescence: 4 images will be taken per slide. Using Zeiss Zen Blue software, a 10 
by 10 grid will be overlayed on the image. This grid will allow us to determine the percent of 
fluorescence positivity in each image taken based on the analysis we are performing. For 
analysis requiring visualization of structural components a brightfield image will also be 
used to determine specific histological structures. Statistical analysis will be a unpaired 1-
Way Anova comparing the mean of each group to the mean of each other group at 95% 
confidence to determine statistical significance.   
Quantitative (Real-Time) Polymerase Chain Reaction (qPCR): RNA will be isolated from 
snap frozen tissue using traditional Trizol extraction methods. RNA will be measured using 
Nanodrop for purity. cDNA will be synthesized using High-Capacity cDNA Reverse 
Transcription Kit (4368814). qPCR will be performed using SYBR Green Real-Time PCR 
Master Mixes (4367659) on QuantStudio™ 7 Flex Real-Time PCR System from 
ThermoFisher.   
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Fibronectin F GCTCAGCAAATCGTGCAGC 
Fibronectin R CTAGGTAGGTCCGTTCCCACT 
Col1α1 F GCTCCTCTTAGGGGCCACT 
Col1α1R CCACGTCTCACCATTGGGG 
LOX F TTCTTCTGCTGCGTGACAACC 
LOX R AATAGGGGTTGTCGTCGGAGT 
TNFa F CCAGTGTGGGAAGCTGTCTT 
TNFa R AAGCAAAAGAGGAGGCAACA 
FGF F GCGACCCACACGTCAAACTA 
FGF R TCCCTTGATAGACACAACTCCTC 
VEGF F AAAGCCAGCACATAGGAGAGATGAG 
VEGF R CTCGAAGAGTCTCCTCTTCCTTCATG 
Ang2 F CAGCCACGGTCAACAACTC 
Ang2 R CTTCTTTACGGATAGCAACCGAG 
CD31 F TGCACAGTGATGCTGAACAA 
CD31 R CCATGAGCACAAAGTTCTCG 
GAPDH F GCAAGGTGTATGAATCTGTGCT  
GAPDH R TCAAGGTAACAAAGAGTGCCA 
TGFβ1 F CACTGGAGTTGTACGGCAGTG  
TGFβ1 R AGAGCAGTGAGCGCTGAATC 
Tie 2 F 1 GAGTCAGCTTGCTCCTTTATGG 
Tie 2 R 1 AGACACAAGAGGTAGGGAATTGA 
Tie 2 F 2 CGGCAGGTACATAGGAGGAA 
Tie 2 R 2 TCACATCTCCGAACAATCAGC 
 
Statistical Analysis: Data are represented as the mean ±SEM. *p < 0.05, **p < 0.01, ****p < 
0.0001. ns, not significant. Analysis of two samples or indicated by comparison bars was 
performed by Unpaired Student’s T-test. Multiple group analysis was performed using One-
way Anova.  
Cell Culture: Renal and lung endothelial cells were obtained from the laboratory of Dr. 
Isaiah Fidler and cultured as previously described ((Langley and Fidler 2003). For 
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Angiopoietin 2 stimulation, 1ug of murine recombinant Angiopoietin 2 (7186-AN-025) was 
added to the culture media for the indicated times. 4T1 cancer cells where tagged with GFP 
and grown to 80-85% confluence. Cells where trypsinized and washed in PBS prior to 
intravenous or orthotopic injection.  
Quantification of metastatic burden and tumor necrosis: Hematoxylin and eosin staining of 
the lung and kidney sections from paraffin-embedded tissue was generated. Image of an 
entire lobe was obtained using the Panoramic 250 Flash III slide scanner. Metastasis were 
identified using via histopathological analysis based on H&E staining and metastatic area 
was quantified using Panoramic Viewer software as a percentage of total lung area. High 
magnification images of the metastatic area are provided for each lung photomicrographs.  
ELISA: Blood was collected at the time of euthanasia and 200ul was spun down at 1500rpm 
for 5 minutes. Serum was separated and stored in -80C. Samples were thawed and 20ug 
was diluted in the sample diluent buffer provided in the Angiopoietin 2 Mouse ELISA kit 
(Abcam ab171335) and the ELISA was then carried out following the manufacturer’s 
directions.  
Western Blot: Cells where grown on 6cm dishes and treated as indicated. Cells were 
washed with PBS and removed from the dish using a cell scraper and transferred to a 1.5ml 
Eppendorf tube. Cells where spun down at 1500rpm for 5 minutes and supernatant 
removed. Cell pellet was resuspended in 200-300ul of RIPA buffer and sonicated every 10 
minutes for 30 minutes at 4C. Lysate was spun at 12,000rpm for 10 minutes and 
supernatant was transferred to a new 1.5ml Eppendorf tube. Protein concentration was 
measured using BCA assay reagents (Pierce). Western blot was run using standard BioRad 
protocol. Membranes were blocked in 5% milk in PBS for 1 hour and incubated in Actin 
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(1:1000 Cell Signaling 4970), pTie2 Tyr1108 (1:100 Thermo Fischer PA5-38339) and pERK 
(1:500 Cell Signaling 9101) overnight in 4C. Membranes were washed and incubated in 
secondary HRP conjugated antibody and exposed. 
Immunofluorescence/ Immunostaining: Harvested tissues, tumor, lungs, and kidneys, and 
skin were fixed in 10% neutral buffered formalin, dehydrated and embedded in paraffin. For 
Sirius Red the deparaffinized tissues were stained in hematoxylin for 8 minutes, washed for 
10 minutes and then stained in Sirius Red solution for 1 hour. Slides where then scanned 
using Pannoramic 250 Flash III slide scanner and quantified on Phostoshop software using 
a 10 by 10 grid to count positive areas for ≥3 fields/tissue per x20 image. Alternatively, 
deparaffinized tissues were incubated in 10mM citrate buffer (ph 6.0) for 15 minutes at 95C 
prior to blocking with 4% Cold Water Fish Gel in PBS. Tissues where incubated overnight in 
following blocking in αSMA(1:500 Sigma C6198), Claudin 5 (1:100 Thermo Fischer 35-
2500), Ki67 (1:500 Abcam ab15580), and Isolectin B4 (1:500 Thermo Fischer I21411) 
followed by secondary fluorescent antibodies. Slides were mounted with DAPI to label 
nuclei. Positive staining was quantified in ≥3 visual fields/tissue at x63 or x100 using 
Photoshop software by placing a 10 by 10 grid to count positive areas or costaining. 
Statistical analysis was done using the average staining per tissue. Stainings were 
visualized on a Zeiss microscope. For the cell culture staining cells where grown on 8 well 
chamber slides and treated as indicated with either PBS or murine recombinant 
Angiopoietin 2. Cells where washed in PBS and fixed for 10 minutes in 4% 
paraformaldehyde then blocked for 1 hour in 4% Cold Water Fish Gel in PBS. Cells where 
incubated overnight in ZO-1 (1:100 Thermo Fischer 61-7300) and Phalloidin (1:1000 
Thermo Fischer T7471).  
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Microarray analysis and quantitative real time PCR analysis: Total RNA was isolated from 
healthy and wounded skin, healthy and fibrotic lungs and healthy and fibrotic kidneys Trizol 
(Invitrogen) and RNA was extracted according to manufacture’s instructions.. An equal 
amout of RNA was submitted from each cohort (n=3) to the Microarray core facility at MD 
Anderson. Microarray analysis was performed using Mouse Ref8 Gene Expression 
Beadchip (Illumina) software. Ingenuity Pathway Analysis (IPA) was performed on the 
microarray data set, with a threshold of 1.2 and 1.5 fold. For RT PCR analyses, tissues 
were homogenized in Trizol (Invitrogen) and RNA was extracted according to manufacture’s 
instructions. cDNA was generated using High Capacity cDNA Reverse Transcriptase Kit 
(Applied Biosytems). Gene expression was determined using Applied Biosystems 7300 
Sequence Detector System and SYBR green as the fluorescence reporter. Measurements 
were standardized to the housekeeping gene (CD31 or GAPDH).  
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Chapter 3: Kidney and Lung Fibrosis express similar pro-tumorigenic factors 
Fibrosis and the tumor microenvironment have been shown to share a number of 
biochemical and biophysical similarities including secreted cytokines. Previous research has 
shown that fibrotic environments are pro-tumorigenic for primary tumor growth and can also 
enhance metastatic growth to organotropic organs. Furthermore, the fibrotic environment 
and the pre-metastatic niche have been also been shown to be similar and the pre-
metastatic niche has been implicated as a potential driving factor towards organotropism. 
The majority of metastasis and organotropic research has been focused on the tropic 
organs while limited research has focused on the organs that rarely develop metastasis. 
Here we choose to focus not only on the tropic organs within breast cancer, but to also 
determine if we created a fibrotic, and thus pro-tumorigenic, pre-metastatic niche 
environment in a non-organotropic organ could we re-route metastasis to that organ. Given 
previous publications implicating the increased levels of TGFβ, LOX, TNFα, Collagen, 
αSMA among other factors in the fibrotic environment, tumor microenvironment and pre-
metastatic niche, we aimed to determine whether this was sufficient to re-route metastasis 
to a non-organotropic organ.  
For the purposes of this study we choose to utilize two well-established mouse 
models of metastatic breast cancer. The mouse derived 4T1 mammary fat pad cancer cell 
line and the MMTV-Pymt models have both been shown to metastasize to multiple organs 
including the lung, liver and brain with similar tropism to human breast cancer. The 
advantage of these models is that they both have consistent temporal tumor growth rates. 
This allows for the induction of specific treatments at known tumor sizes providing for a 
consistency across the two models. Furthermore, both of the models are in the BALB/c 
background allowing for the comparison of the two different breast cancer models. Currently 
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there are no studies utilizing these models to determine whether they can be rerouted to 
metastasize to a non-tropic organ. It has been shown that direct injection of 4T1 cells into 
the kidney can form a tumor within the cortex indicating that if capable of entering the 
parenchymal space of the kidney these cells would be capable of forming a metastatic 
nodule.  
To elucidate the contribution and control of the fibrotic environment on metastasis 
we evaluated three models of tissue damage in 4T1 and MMTV-Pymt tumor bearing mice. 
By inducing a cutaneous wound, lung fibrosis and kidney fibrosis we can observe a normal 
resolving wound, an organotropic fibrosis and a non-organotropic fibrosis effect on 
metastatic spread in breast cancer. Given that clinically surgery, a wound, has not been 
shown to enhance metastasis and other research has indicated that pro-fibrotic factors go 
down by day 7 in normal resolving wounds in mice the wound will act as the control for 
normal kinetics. Comparison of the wound to the lung fibrosis and kidney fibrosis allows us 
to compare acute normal wound versus chronic fibrotic damage. Utilizing Bleomycin to 
induce lung fibrosis we aim to develop a pro-tumorigenic environment in an organotropic 
organ, while surgically induced kidney fibrosis will act as the non-organotropic organ.  
Based on the pro-tumorigenic and pro-metastatic nature of the fibrotic environment 
and its secreted cytokines, we hypothesized that both lung fibrosis and kidney fibrosis 
would have the necessary factors to enhance metastasis in a systemic manner. In 
accordance with previous studies we expect to see an increase in metastasis to the fibrotic 
lung, and given the induction of a similar pro-tumorigenic environment in the fibrotic kidney 
we would hypothesize that this would induce metastatic growth in the damaged non-
organotropic organ.  
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 Histopathological characterization of cutaneous wound, lung fibrosis and kidney 
fibrosis shows increased collagen deposition and aSMA+  
To understand the role of the fibrotic environment in breast cancer metastasis we 
began by evaluating and comparing the pro-tumorigenic factors expressed in a resolving 
wound, lung fibrosis and kidney fibrosis. Cutaneous wound skin at day 6 post injury (an 
open wound), Bleomycin induced fibrotic lungs, and surgically induced fibrotic kidneys 
where harvest at day 10 post insult. The insulted organs where each stained with H&E, 
Sirius Red and immunofluorescently stained with aSMA. Morphometric analysis for Sirius 
Red and aSMA was performed comparing each fibrotic organ with its healthy control. Sirius 
Red is a cationic dye that binds by reacting to the basic groups in collagen. The dye binds 
to the collagen molecules in a parallel orientation, which results in an increased bifringency 
and is counterstained with pictoric acid and hematoxylin for nuclear stain. An increase in 
positive red area indicates an increase in collagen. There is a significant increase in Sirius 
Red positive areas in the skin wound at day 6 and both lung and kidney fibrosis (Figure 
16B,D,F,H). Additionally, aSMA, a marker for the collagen depositing myofibroblasts is also 
significantly increased in the day 6 wound, and lung and kidney fibrosis. (Figure 16C, 
E,G,I). Taken together these results indicate that an open wound, lung and kidney fibrosis 
all show increases in the production of fibrotic tissue.  
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Figure 16: Histology of fibrosis in skin, lung and kidney. A) H&E of healthy skin, wounded skin, 
healthy lung, fibrotic lung, healthy kidney, and fibrotic kidney. B) Sirius Red of healthy skin, 
wounded skin, healthy lung, fibrotic lung, healthy kidney, and fibrotic kidney. C) aSMA 
immunofluroscence of healthy skin, wounded skin, healthy lung, fibrotic lung, healthy kidney, and 
fibrotic kidney. D) Quantification of skin Sirius Red. E) Quantification of skin aSMA. F) Quantification 
of lung Sirius Red. G) Quantification of lung aSMA. H) Quantification of kidney Sirius Red. I) 
Quantification of kidney aSMA. Scale bar=25um.Data are represented as the mean ±SEM using 
Student’s T-test for *p < 0.05, **p < 0.01, ****p < 0.0001. ns, not significant. 
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Fibrotic environments show sustained increased chronic expression of  
pro-tumorigenic factors 
 Given that healthy wounds begin resolving and are typically fully closed in healthy 
mice by day 10-17, versus fibrosis which persists beyond day 10 post insult we performed 
Illumina gene expression arrays on skin at day 6 and day 17 post injury, and on fibrotic and 
healthy lungs and kidneys. Using previous publications, we compiled a list of genes shown 
to be present in the pre-metastatic niche and to be pro-tumorigenic. The open wound and 
closed wound were normalized to healthy unwounded skin, while the fibrotic lung and 
fibrotic kidney where normalized to a healthy respective organ. By comparing the differential 
gene expression levels in a healthy open wound versus a healthy closed wound it is evident 
that the pro-tumorigenic genes do not significantly increase their expression and/or return to 
basal levels once the wound is closed. Conversely, when both the fibrotic lung and fibrotic 
kidney are compared to their respective healthy control organ at day 10 post insult a 
number of genes associated with pro-tumorigenic growth are still upregulated (Figure 17). 
To confirm the chronic upregulation we performed qPCR on select genes to confirm their 
upregulation at day 10 in the kidney fibrosis models (Figure 18). 
 The sustained increase in similar pro-tumorigenic factors in the fibrotic lung and 
kidney versus the resolved factors in the wound will enable us to test the effects of forming 
a pro-tumorigenic environment in the tropic and non-organotropic organ.  
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 Figure 17: Increase in expression of genes 
associated with pre-metastatic niche in the fibrosis 
environment. Probes fluorescent units are shown in 
log scale. N=3 for each group.  
 
 
Healthy 
Skin
Open 
Wound
Closed 
Wound
Healthy 
Lung
Fibrotic  
Lung
Healthy 
Kidney
Fibrotic 
Kidney
Lox 3.07516 2.99499 3.51942 3.19066 3.96621 3.67244 4.07286
S100a9 2.52799 2.95912 2.47023 2.96241 3.57985 3.51871 3.91676
Col2a1 0.82962 1.28102 1.07378 1.01479 2.87156 2.2508 3.89936
Egfr 1.48372 1.31751 1.54426 1.14661 2.82625 2.25604 3.85253
Tnfsf11 1.11608 1.32976 1.31108 1.98621 2.57638 3.19077 3.80382
Col4a5 2.42596 2.17558 2.09437 1.92902 2.5956 2.78117 3.65615
Fn1 1.74539 1.64242 2.16098 2.45451 3.01414 3.56865 3.64291
Tnc 1.12137 1.63376 1.3383 1.17239 2.46639 2.56055 3.62416
Fgf5 1.70817 1.62636 2.21022 2.03669 2.83057 3.22394 3.57394
Col4a4 1.18115 0.79161 1.24613 3.24429 3.1767 3.71251 3.54702
Col2a1 1.26176 1.32693 1.07301 1.54373 2.37888 3.14634 3.48971
Fgf1 1.40207 1.1788 1.22497 1.36244 2.52038 1.86251 3.44674
Tnc 2.11921 2.68497 2.61349 3.31644 3.0477 3.57746 3.4245
Pgf 1.09858 1.19162 1.28294 1.41341 2.43486 1.8195 3.36082
Bmp1 3.32336 3.40661 3.41699 1.42514 2.32591 2.37397 3.23717
S100a8 3.06729 3.46458 3.00079 2.18961 2.87175 2.93829 3.12252
Tnc 0.5744 0 0 2.75454 2.61335 3.16644 3.05962
Mmp9 2.09755 2.48452 2.03868 2.82927 3.04739 2.73911 3.00835
Vcam1 0 0.95053 0.84107 2.16958 3.06282 2.91328 2.95902
Egfr 2.38 2.33424 2.42526 3.03257 2.7595 3.19395 2.95499
Bmp1 2.67688 2.83847 3.04746 3.05755 2.84022 2.65884 2.85478
Col3a1 3.15878 2.90131 3.4211 2.84716 2.50255 2.55714 2.76221
Vegfa 2.75737 2.83327 2.53691 2.58851 2.68738 2.9303 2.70316
Mmp2 3.87634 3.93833 4.10482 1.50605 2.39911 2.48027 2.69469
Col1a1 3.87219 3.82965 3.90811 1.58152 2.33967 2.41593 2.68331
Fn1 3.0167 3.20661 3.48508 1.33133 2.10299 2.08419 2.67964
Col1a2 2.52293 2.66912 2.907 2.61653 2.08288 1.94897 2.62145
Icam1 2.59898 2.66762 2.77833 2.56603 1.93394 2.62557 2.56651
Hif1a 2.19976 1.81598 2.11418 2.27009 2.05307 1.85555 2.47642
Csf1 1.9531 2.19934 2.18274 1.19512 1.58642 1.72339 2.46989
Hgf 1.05806 1.32256 1.35914 1.63885 2.28366 2.48026 2.4544
Tnf 1.62469 1.39708 1.43867 1.43708 1.40927 1.76283 2.37243
Timp1 2.25759 2.78318 2.84318 2.24454 2.11981 2.29104 2.30543
Bmp1 2.72837 2.89092 3.08015 2.46205 2.272 2.18203 2.30318
Csf3 1.29238 1.42205 1.40061 1.46876 1.86449 2.26442 2.30228
Egfr 3.30709 3.09667 3.12687 1.08085 1.37059 1.68059 2.26762
Col4a4 1.57483 1.11538 1.53388 1.24054 1.27396 1.50652 2.25393
Col3a1 2.85899 2.38077 2.10783 2.43231 2.15422 2.11218 2.16594
Tgfb1 1.96307 2.30993 2.25692 2.11976 1.8621 2.49792 2.13853
Tnc 1.17956 1.4138 0.7979 1.00206 1.2666 1.60306 2.09738
Cxcl12 2.7264 2.76148 2.80516 1.27767 1.92381 2.04381 2.08667
Vegfa 2.21878 2.40585 2.09912 2.33723 2.08814 1.9554 1.97809
Col4a1 3.41646 3.31531 3.65304 1.45265 1.49612 1.76201 1.91993
S100a4 2.13106 2.05779 2.27296 1.15885 2.05593 2.18249 1.91554
Tnf 1.27524 1.26078 1.06739 1.45757 1.44886 1.59642 1.88886
Col4a5 2.01362 1.92238 1.993 1.12722 1.39618 1.65973 1.79192
Col4a6 1.03995 1.05944 1.03041 1.14556 1.3985 1.48253 1.71283
Hgf 1.03937 0.98032 1.06239 1.1566 1.38243 1.60542 1.65289
Cxcl12 2.55536 2.7018 2.51801 1.29762 1.42976 1.67404 1.64661
Col4a3 1.38324 1.24115 1.35518 1.05609 1.14629 1.5022 1.60297
Fn1 0.64991 1.08793 1.21446 0.72173 1.11748 1.49549 1.60108
Cxcl12 3.19471 3.22633 3.1383 1.25097 1.28119 1.59152 1.59509
Tnc 2.02675 2.63619 2.49761 1.34475 1.30371 1.56971 1.5896
Col4a2 3.14479 3.28968 3.41125 1.30921 1.29608 1.51072 1.58268
Egfr 2.27099 2.27177 2.26764 1.18884 1.24272 1.5265 1.58082
Fgf1 2.00836 1.8891 1.98608 0.29011 1.10437 1.55939 1.56979
Timp1 2.15812 2.78285 2.79905 1.22848 1.20551 1.54661 1.54392
Hif1a 0 0.97212 0 1.11172 1.30132 1.57073 1.50972
Vcam1 1.90279 2.29729 2.55015 1.18701 1.05701 1.61636 1.48801
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Figure 18: Fold Change expression for genes associated with the pre-metastatic niche and tumor 
microenvironment in kidneys of indicated groups. The fold change in TGFB1, Fibronectin, Col1a1, 
LOX, TNFa, FGF and VEGF in healthy kidneys, contralateral kidneys, fibrotic kidneys and the 
kidneys of mice treated with bleomycin. Normalized to GAPHD. Data are represented as the mean 
±SEM using One-Way Anova for *p < 0.05, **p < 0.01, ****p < 0.0001. ns, not significant. 
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Chapter 4: The effect of organotropic and non-organotropic fibrosis on breast 
cancer metastasis 
To test the capacity of pro-tumorigenic fibrosis to enhance and/or reroute metastatic 
disease we induced cutaneous skin wound, lung fibrosis, or kidney fibrosis in mice that 
received 1) orthotropic 4T1 injections 2) intravenous 4T1 injections 3) or MMTV-Pymt tumor 
bearing mice. By injecting 4T1 cancer cells orthotopically and utilizing the MMTV-Pymt 
model we are able to model the spread of metastatic disease from the primary tumor 
following the metastatic cascade. The use of the intravenous model allows us to remove 
any influence from the primary tumor and to test the effects of fibrosis on both vasculature 
and extravasation and on other host organs.   
The effect of cutaneous skin wound on breast cancer metastasis 
A long-standing concern within the surgical community has been the effect of 
surgery on the spread of metastatic disease. Although there is limited evidence to show that 
surgical wounds promote metastatic disease, and given that pro-tumorigenic factors from 
wounds resolve after a few days we opted to determine whether induction of a cutaneous 
wound could have any effects on the spread of metastatic disease. Mice where initially 
injected bilaterally with 4T1 cancer cells into their mammary fat pads and monitored for 
tumor growth. Once the 4T1 tumors had reached a combined growth of 500mm3 the mice 
where anesthetized and an 8mm dorsal non-peritoneal penetrating wound was surgically 
induced. The same progression was used for the MMTV-Pymt with mice receiving a wound 
once the combination of their tumors had reached a combined 500mm3. Once the tumors 
reached a combined 1500mm3 the mice were euthanized and tissues collected for analysis. 
Additionally, we injected 4T1 cancer cells intravenously and induced wound on the same 
day. Given the propensity for both these models to metastasize to the lungs we primarily 
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focused our metastatic analysis on the pulmonary system. We also collected the kidneys 
from all mice to analyze for potential metastatic spread and to compare to the other cohorts 
with fibrotic lung and kidney. 
To compare metastatic spread in mice with and without cutaneous wound we 
performed H&E staining on the lungs and kidneys and counted metastasis microscopically. 
As hypothesized, there was no significant difference between metastatic spread to the lungs 
in the mice with and without cutaneous wound in either the 4T1 (Figure 19E, F, G) model or 
the MMTV-Pymt model (Figure 19A, C, D). Similarly, we noted no difference in colonization 
of the lungs in the intravenous 4T1 with or without cutaneous wound (Figure 19I, K, L). 
There was no metastatic growth or colonization of the kidneys in any these mice (Figure 
22A, B). There was no change in the growth rates of the tumors (Figure 19B, I).  
 
 
 
 
 
 
 
 
 
 
C o n tro l S k in
W o u n d
0 .0 0
0 .1 0
0 .2 0
0 .3 0
M
e
ta
s
ta
ti
c
 a
re
a
 (
%
)
ns
C o n tro l S k in
W o u n d
0
5
1 0
1 5
#
 o
f 
S
u
rf
a
c
e
L
u
n
g
 N
o
d
u
le
s
ns
C o n tro l F ib ro t ic
L u n g
0 .0 0
0 .2 0
0 .4 0
0 .6 0
M
e
ta
s
ta
ti
c
 a
re
a
 (
%
) *
C o n tro l F ib ro t ic
L u n g
0
5
1 0
1 5
2 0
2 5
#
 o
f 
S
u
rf
a
c
e
L
u
n
g
 N
o
d
u
le
s
***
C o n tro l F ib ro t ic
K id n e y
0 .0 0
0 .0 5
0 .1 0
0 .1 5
0 .2 0
0 .2 5
M
e
ta
s
ta
ti
c
 a
re
a
 (
%
) **
C o n tro l F ib ro t ic
K id n e y
0
5
1 0
1 5
#
 o
f 
S
u
rf
a
c
e
L
u
n
g
 N
o
d
u
le
s ***
A
 
B
 
C
 
D
 
61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Metastatic Analysis in Cutaneous Wound A) Histological representation of MMTV-Pymt 
metastasis with and without cutaneous wound. B) Pymt Tumor growth curve C) Metastatic and D) surface 
lung nodule quantification of MMTV-Pymt mice with and without cutaneous wound. E) Histological 
representation of 4T1 orthotopic metastasis with and without cutaneous wound. F) Metastatic, G) surface 
lung nodule quantification and H) CTC analysis of 4T1 orthotopic mice with and without cutaneous wound. 
I) Histological representation of 4T1 IV metastasis with and without cutaneous wound. J) 4T1 Orthotopic 
growth curve K) Metastatic and L) surface lung nodule quantification of 4T1 IV mice with and without 
cutaneous wound. N=6 for each group. Scale bar=25um. Data are represented as the mean ±SEM using 
Student’s T-test for *p < 0.05, **p < 0.01, ****p < 0.0001. ns, not significant. 
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The effects of lung fibrosis on breast cancer metastasis 
Using the same methodology as in with the cutaneous wound we induced lung 
fibrosis in 4T1 orthotopic, 4T1 intravenous, and MMTV-Pymt mouse models of breast 
cancer either once the tumors had reached 500mm3 or on the same day as 4T1 intravenous 
injection. These mice were euthanized 10 days post intratracheal Bleomycin lung fibrosis 
inducing surgery. The 10 days euthanization was both for humane reasons and also due to 
the rapid progression of metastatic disease in these mice. Analysis of these mice revealed 
significant spread of 4T1 (Figure 20 E, F, G) and Pymt (Figure 20 A, C, D) metastasis and 
colonization (Figure 20I, K, L) of the lungs in mice with lung fibrosis as compared to mice 
that received only intratracheal PBS injections. None of these had metastasis to their 
kidneys (Figure 22) or changes to their tumor growth (Figure 20B, J). The increased 
metastasis and colonization of the fibrotic lungs in these mice indicates that the pro-
tumorigenic fibrotic environment is able to enhance metastatic spread to organotropic 
organs. These results reflect previous publications and support the role of the 
aforementioned pro-tumorigenic factors in promotion of metastasis.  
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Figure 20: Metastatic Analysis in Lung Fibrosis A) Histological representation of MMTV-Pymt metastasis with 
and without lung fibrosis. B) Pymt Tumor growth curve C) Metastatic and D) surface lung nodule quantification 
of MMTV-Pymt mice with and without lung fibrosis. E) Histological representation of 4T1 orthotopic metastasis 
with and without lung fibrosis. F) Metastatic, G) surface lung nodule quantification and H) CTC analysis of 4T1 
orthotopic mice with and without lung fibrosis. I) Histological representation of 4T1 IV metastasis with and 
without lung fibrosis. J) 4T1 Orthotopic growth curve K) Metastatic and L) surface lung nodule quantification of 
4T1 IV mice with and without lung fibrosis. N=6 for each group. Scale bar=25um. Data are represented as the 
mean ±SEM using Student’s T-test for *p < 0.05, **p < 0.01, ****p < 0.0001. ns, not significant. 
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The effects of kidney fibrosis on breast cancer metastasis 
To elucidate the ability of the pro-tumorigenic fibrotic environment to potentially 
reroute metastasis to a non-organotropic organ we surgically induced kidney fibrosis 
utilizing the same 4T1 and MMTV-Pymt methods and models and time course as the lung 
fibrosis cohort. Given the presence of chronically and significantly upregulated expression 
of pro-tumorigenic factors in the fibrotic kidney and publications reporting the chemotactic 
properties of upregulating these factors on cancer cells we surmised that this environment 
should reroute metastatic spread to the damaged kidney. Surprisingly, upon euthanization 
of the mice with kidney fibrosis there was no macroscopically apparent metastatic nodules 
in the 4T1 orthotopic, MMTV-Pymt of the 4T1 intravenous model (Figure 22A, B). Further 
histological analysis of the kidneys confirmed the induction of fibrosis, and that despite the 
development of this pro-tumorigenic environment, fibrosis was not able reroute metastatic 
spread to a non-organotropic organ. This result indicates that while the previously reported 
pro-tumorigenic factors found in the pre-metastatic niche are sufficient to enhance 
metastasis to an already tropic organ, they are not sufficient to redirect metastatic spread. 
The inability of the fibrotic environment to redirect metastatic disease indicates that there 
are additional factors that affect metastatic tropism in addition to the previously reported 
pre-metastatic niche alterations that occur in the tropic organs.  
In addition to noting that fibrosis could not redirect metastatic disease to the non-
tropic kidney we also analyzed metastasis in the lungs of mice with kidney fibrosis. 
Histopathological analysis revealed there was an increase in metastasis to the lungs of 
mice that had kidney fibrosis. Increased lung metastasis was observed in the 4T1 orthotopic 
model (Figure 21A, C, D) Similarly, metastasis to the lung was enhanced in the MMTV-
Pymt model (Figure 21E, F, G) and also in the 4T1 intravenous model (Figure 21 I, K, L) 
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with kidney fibrosis. There was no effect of kidney fibrosis on primary tumor growth (Figure 
21B, J). These results indicate that kidney fibrosis is able to systemically affect distant 
organs to enhance metastasis and colonization. However, given the similarities between the 
fibrotic environment, the tumor microenvironment, and the pre-metastatic niche this effect 
appears to be unrelated to the molecules that have previously been associated with 
determination of metastatic organotropism. 
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Figure 21: Metastatic Analysis in Kidney Fibrosis A) Histological representation of MMTV-Pymt metastasis 
with and without kidney fibrosis. B) Pymt Tumor growth curve C) Metastatic and D) surface lung nodule 
quantification of MMTV-Pymt mice with and without kidney fibrosis. E) Histological representation of 4T1 
orthotopic metastasis with and without kidney fibrosis. F) Metastatic, G) surface lung nodule quantification 
and H) CTC analysis of 4T1 orthotopic mice with and without kidney fibrosis. I) Histological representation 
of 4T1 IV metastasis with and without kidney fibrosis. J) 4T1 Orthotopic growth curve K) Metastatic and L) 
surface lung nodule quantification of 4T1 IV mice with and without kidney fibrosis. N=6 for each group. 
Scale bar=25um. Data are represented as the mean ±SEM using Student’s T-test for *p < 0.05, **p < 0.01, 
****p < 0.0001. ns, not significant. 
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Figure 22: Metastasis did not spread to the kidneys despite the fibrotic environment. A) 
Representative images of kidneys from each cohort showing no metastatic growth. B) 4T1 GFP 
labelled cells where visualized in the tumor and lung metastasis, but could not be located in the 
kidneys of mice from any cohort. Scale bar=25um. 
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Chapter 5: Kidney fibrosis increases the circulating levels of cytokines known 
to affect vasculature  
The finding that fibrosis cannot reroute metastatic disease, but can systemically 
enhance the spread to tropic organs indicates that the fibrotic environment, similar in nature 
to the primary tumor microenvironment releases factors that travel systemically and effect 
various aspects of the host in an organ-specific manner. Given that in both the fibrotic lung 
and fibrotic kidney there were significant increases in the presence of pro-tumorigenic 
molecules in the stromal microenvironment we hypothesized that this organ-specific 
reaction to circulating fibrotic cytokines might occur within a non-stromal aspect of the 
organ.  
Chronically elevated circulating cytokines during kidney fibrosis 
To determine the cytokines elevated during fibrosis we initially performed an analysis 
using Ilumina array data of fibrotic kidneys as compared to their healthy kidneys. Utilizing 
genes that were increased in the fibrotic kidneys we performed pathway and gene ontogeny 
analysis using the online software DAVID. Analysis of this data revealed significant changes 
associated with both tight junctions and with vascular remodeling (Figure 23,24, 25). 
Categorical analysis revealed a number of vascular related genes upregulated in the fibrotic 
kidneys when compared to healthy kidneys. While these factors are associated with 
alterations in tight junction structure and vasculature further experimentation was required 
to determine which of the factors was also secreted into the circulation.  
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Healthy Kidney Fibrotic Kidney 
Figure 23: Heat Map of genes differentially expressed in healthy 
kidneys versus fibrotic kidneys.  N=3 for each cohort.  
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A
 Category Term Count % P-Value Benjamini
GOTERM_BP_FAT regulation of transcription 517 12.8 3.60E-05 3.40E-03
GOTERM_BP_FAT transcription 432 10.7 1.20E-06 2.40E-04
GOTERM_BP_FAT intracellular signaling cascade 247 6.1 1.30E-07 6.40E-05
GOTERM_BP_FAT phosphate metabolic process 229 5.7 2.20E-06 3.60E-04
GOTERM_BP_FAT phosphorus metabolic process 229 5.7 2.20E-06 3.60E-04
GOTERM_BP_FAT cell cycle 195 4.8 1.70E-12 7.30E-09
GOTERM_BP_FAT phosphorylation 195 4.8 2.20E-06 3.70E-04
GOTERM_BP_FAT protein amino acid phosphorylation 188 4.7 8.50E-09 7.20E-06
GOTERM_BP_FAT cell adhesion 177 4.4 5.80E-11 1.20E-07
GOTERM_BP_FAT biological adhesion 177 4.4 6.90E-11 9.70E-08
Category Term Count % P-Value Benjamini
KEGG_PATHWAY Pathways in cancer 91 2.3 2.80E-04 4.00E-03
KEGG_PATHWAY MAPK signaling pathway 85 2.1 2.60E-06 1.20E-04
KEGG_PATHWAY Focal adhesion 71 1.8 2.10E-07 1.30E-05
KEGG_PATHWAY Regulation of actin cytoskeleton 65 1.6 4.20E-04 5.20E-03
KEGG_PATHWAY Chemokine signaling pathway 56 1.4 5.50E-04 6.00E-03
KEGG_PATHWAY Cell adhesion molecules (CAMs) 53 1.3 3.40E-05 8.90E-04
KEGG_PATHWAY Cell cycle 52 1.3 1.40E-07 1.30E-05
KEGG_PATHWAY Endocytosis 52 1.3 3.80E-02 1.50E-01
KEGG_PATHWAY Tight junction 46 1.1 1.60E-04 2.40E-03
KEGG_PATHWAY Neurotrophin signaling pathway 45 1.1 1.30E-04 2.10E-03
B
 
Figure 24: Gene Ontogeny and KEGG analysis from DAVID. A) The top 10 gene ontogeny terms of 
upregulated genes in fibrotic kidneys as compared to healthy kidneys. B) The top 10 pathway terms 
upregulated in fibrotic kidneys as compared to healthy kidneys.  
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Based on the results of our gene array we selected a cytokine array from R&D 
systems and ran multiple samples from healthy, cutaneous wound, fibrotic lung, and fibrotic 
kidney serum. While a number of cytokines were increased in the serum of mice with 
fibrosis as compared to the healthy and wounded serum, we noted that Angiopoietin 2 was 
elevated both in our gene array data (Figure 25A) and in the serum of mice with kidney 
fibrosis (Figure 25B, 26). To confirm our observations from the cytokine array we 
performed an Angiopoietin 2 specific ELISA on the serum of all the cohorts and their 
respective controls. In accordance with previously published data our basal levels of 
Angiopoietin 2 were around 2000pg/ml. Most notably the serum Angiopoietin 2 levels of 
mice with kidney fibrosis were significantly elevated (Figure 27). Interestingly, Angiopoietin 
2 was not as elevated in the serum of mice with lung fibrosis as compared to the serum of 
mice with healthy lungs (Figure 27). Furthermore, we also confirmed that in the fibrotic 
kidney the gene expression of Angiopoietin 2 was increased (Figure 27).  
 These results suggest that fibrotic kidney damage releases continuous Angiopeotin2 
into circulation at significantly elevated levels. Given that Angiopoietin 2 has been shown to 
be an antagonist of Angiopoietin 1 and a destabilizer of endothelium cell-cell interactions 
and tight junctions, we surmised that this could cause systemic alterations in vascular 
permeability leading to increased likelihood of extravasation of circulating cancer cells.  
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Healthy 
Kidney
Fibrotic 
Kidney
Angpt2 2.686827066 2.944020161
Angptl4 0.440827707 1.220089674
Arsi 1.151590481 1.31937287
Bmper 1.213160756 1.630819299
C1qtnf1 1.480110129 2.072651677
Car11 1.930841761 2.20601871
Cbln4 0.906188688 1.179973631
Ccdc80 1.788511187 2.411386852
Ccl27 1.825537314 2.094441672
Ccl4 1.559123474 2.250242769
Ccl6 1.301543707 1.909055509
Ccl7 0.953635732 2.130140806
Ccl9 1.532162764 2.769567054
Cd200 1.235598141 1.630507323
Chi3l1 1.448993189 2.008385578
Chi3l3 0.866542544 1.426706553
Col5a2 1.011755999 1.49785646
Cort 0.968446991 1.227021643
Crim2 0.780308201 1.150787709
Crlf1 1.203350984 2.298479233
Csnk 0.666864813 1.37453911
Cst3 3.728588169 3.97733859
Cxcl1 1.985125312 3.100307702
Cxcl14 1.444282125 2.175404193
Cxcl16 1.666921676 2.113569709
Cxcl4 1.474289059 2.120267093
Cyr61 1.214319614 1.728536391
Defb1 0.508914138 0.887503202
Defb12 0.859861173 1.135325017
Defb13 1.083088772 1.355366568
Defb14 1.135813339 1.327082405
Defb25 1.19918823 1.55391393
Defcr6 1.14912075 1.370985645
Dkk3 2.561431809 3.002888414
Dmkn 1.178484511 1.46265147
Dpt 1.348692376 1.718518532
Emb 2.848215967 3.157201867
Emid2 1.863537392 2.41603864
Emilin1 1.914819011 2.317480076
Emilin2 1.439800124 2.078150069
Enam 0.66116617 1.067965168
Fam132b 0.928016812 1.375539206
Fgfbp1 1.359104123 1.715048026
Fgl2 0.775854487 1.333961836
Folr4 0.809812895 1.310729142
Gdf15 2.177485949 2.956504554
Gfod2 1.990271917 2.336560821
Gm414 0.990688003 1.296727894
Gm885 1.416115045 1.648327847
Gpx7 1.388463733 2.072632227
Havcr1 2.800393438 3.399482044
Ifna14 0.684274471 1.108147458
Igfbp1 1.017225321 1.342670058
Igfbp2 1.073919534 1.57076488
Igfbp6 1.137756888 1.453251027
Il17re 2.213389314 2.577406393
Il1f6 1.001721353 1.382612984
Il33 1.847048398 2.744233806
Ins1 1.02997853 1.316344332
Insl3 1.840328794 2.363545168
Kazald1 1.015736236 1.304760542
Kng1 2.661470364 2.997066779
Lcn2 1.673118004 3.511398968
Lcn4 1.114687036 1.430200166
Leap2 0.954293095 1.354988814
Lefty2 0.480528707 1.23418946
Lgals3bp 2.68997375 3.264611777
Liph 1.268710829 1.620070149
Ly86 1.601905932 2.348240152
Ly96 1.76402301 2.095665463
Lyz 3.105823828 3.846208793
Lyzs 1.855726435 2.655825017
Matn2 0.915509488 1.261216419
Metrnl 1.410531653 1.621258078
Mfap3 2.445204259 2.729570223
Mfap5 0.957038325 1.670752653
Muc2 0.929690555 1.218831046
Mxra8 2.278854884 2.678994299
Myoc 0.854172622 1.369251352
Nbl1 2.250096554 2.771443332
Nmu 0.832322176 1.130778531
Npff 1.376690753 1.593261903
Oit1 1.135063746 1.513477203
Olfm1 2.30018405 2.676212549
Olfml2b 1.630940008 2.06579486
Olfml3 2.483315186 2.965838441
ORF9 1.146817664 1.541802298
Pcolce2 1.244285569 1.728113857
Pdgfrl 1.070289172 1.370074261
Pglyrp 1.156006414 1.347330874
Pla1a 2.537746331 2.876818776
Prss23 1.47141378 1.943230841
Figure 25: Vascular Adhesion Related Genes and Cytokine array in 
multiple models of fibrosis. A) Genes associated adhesion and tight 
junctions compared in healthy kidneys versus fibrotic kidneys. Probes 
fluorescent units are shown in log scale. B) Heatmap of cytokines from 
serum of healthy mice, mice with a cutaneous wound at day 10, mice 
with lung fibrosis at day 10, and mice with kidney fibrosis at day 10. N=4 
for healthy and wounded, and n=6 for fibrotic lung and fibrotic kidney.  
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Figure 26: Quantitative Analysis of Serum Cytokine Array. The quantification of each cytokine in the 
cytokine array. Data are represented as the mean ±SEM using One-Way Anova T-test for *p < 0.05, 
**p < 0.01, ****p < 0.0001. ns, not significant. 
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Chapter 6: Circulating Angiopoietin -2 alters vasculature in organ specific 
manner 
The finding that fibrotic kidney increases circulating levels of Angiopoietin 2 led us to 
look into how Angiopoietin 2 might influence organ vasculature in different manners and 
whether this could have an effect on organotropism. This is of particular importance as 
elevated levels of circulating Angiopoietin 2 have been linked with multiple pathologies 
including diabetic retinopathy, pulmonary edema during sepsis, and a decrease in disease 
free survival in breast cancer patients and thus a worse prognosis.  
Given that the fibrotic kidney was found to have an upregulated expression of 
Angiopoietin 2, but yet did not develop metastasis we hypothesized that the vascular 
response to Angiopoietin 2 may be different in varying organs. Given the various forms and 
functions of the mammalian organs it is reasonable that in addition to having physically 
Figure 27: Increased serum and fibrotic kidney expression of Angiopoietin 2. A) Angiopoietin 2 ELISA 
comparing healthy, wounded, PBS treated lung, Bleomycin fibrotic lung, contralateral kidney and UUO 
induced fibrotic kidney serum for Angiopoietin 2. N=4 B) qPCR for Angiopoietin 2 expression in healthy 
kidney, contralateral kidney, UUO induced fibrotic kidney, and kidney of mice with lung fibrosis. N=3 per 
cohort.  Data are represented as the mean ±SEM using Student’s T-test for *p < 0.05, **p < 0.01, ****p < 
0.0001. ns, not significant. 
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different endothelium (continuous, fenestrated, and sinusoidal) each different organ may 
respond to similar cytokines in different manners.  
Differential Vascular permeability responses in the lungs and kidneys of mice treated 
with Angiopoietin 2 
In order to assess the vascular permeability in vivo we utilized FITC labelled dextran 
(70,000kDa) injected into mice after two rounds of treatment with 100ug of Angiopoietin 2 
intravenously. Control mice received PBS on the same day as the Angiopoietin 2 injections. 
The lungs and kidneys were harvested from these mice and histological analysis was 
performed on formalin fixed sections after antigen retrieval. By utilizing formalin fixed 
sections, as opposed to frozen OCT we are able to get a significantly better visualization of 
histological structure and thus a more precise analysis of location of FITC positivity. By 
counterstaining with Isolectin B4 we can visualize vasculature and differentiate between 
vascular spaces and parenchymal tissue. Analysis of the lungs of the mice treated with 
Angiopoietin 2 clearly showed an increase in FITC positivity in parenchymal spaces (Figure 
28A, B). In comparison the lungs of the mice treated with PBS showed specific localization 
of FITC to within vessels in the lungs. These finding clearly indicate that elevated circulating 
Angiopoietin 2 induced pulmonary vascular leakage.  
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 Utilizing the same methodology, we also analyzed the effect of Angiopoietin 2 on the 
vasculature of the kidney. In stark contrast to the increased vascular leakage found in the 
lungs of mice treated with Angiopoietin 2, there was no difference in FITC analyzed 
vascular leakage of the kidney between the mice treated with Angiopoietin 2 compared to 
the PBS treated mice. Given that the kidney consists of the cortex, outer medulla, and inner 
medulla, all of which have different vascular physiology we analyzed all three areas for 
potential vascular leakage. Yet, despite the highly vascular nature of the kidney we noted 
no permeability difference between PBS and Angiopoietin 2 in the peritubular capillaries or 
the vasa recta capillaries (Figure 29A, B). Given that the lungs and kidneys were harvested 
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Figure 28: Increased dextran leakage in lungs of mice treated with 
Angiopoietin 2. A) Representative immunofluorescent images of 
the lungs of mice treated with PBS versus Angiopoietin 2 and 
stained for Isolectin-B4. N=5 for each cohort. B) Quantification of 
FITC positivity in perivascular parenchymal spaces in PBS versus 
Angiopoietin 2 treated mice lungs. Scale bar=25um. Data are 
represented as the mean ±SEM using Student’s T-test for *p < 
0.05, **p < 0.01, ****p < 0.0001. ns, not significant. 
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from the same mice we concluded that vascular endothelial response to circulating 
cytokines such as Angiopoietin 2 is organ specific.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: No dextran leakage in kidneys of mice treated with Angiopoietin 2. A) Quantification of 
FITC positivity in perivascular parenchymal spaces in PBS versus Angiopoietin 2 treated mice 
kidneys in the cortex, outer medulla and inner medulla. B) Representative immunofluorescent images 
of kidneys of mice treated with PBS versus Angiopoietin 2 and stained for Isolectin-B4 in the kidney 
cortex. C) Representative immunofluorescent images of kidneys of mice treated with PBS versus 
Angiopoietin 2 and stained for Isolectin-B4 in the kidney outer medulla. D) Representative 
immunofluorescent images of kidneys of mice treated with PBS versus Angiopoietin 2 and stained for 
Isolectin-B4 in the kidney inner medulla. N=5 per cohort. Scale bar=25um. Data are represented as 
the mean ±SEM using Student’s T-test for *p < 0.05, **p < 0.01, ****p < 0.0001. ns, not significant. 
 
 
. 
N=5 for each cohort.  
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 To analyze the pathological vascular effects of wounds, lung fibrosis and kidney 
fibrosis on the lungs we performed histological analysis of the lungs from the mice with 
wounds, fibrotic lung or fibrotic kidneys. Edema was measured by finding the area of 
positive edema in both alveolar and pleural spaces. Pleural thickness was measured by 
measuring the thickness of the lung pleura at 8 areas in each different lung. Our analysis 
showed the lungs of mice with kidney fibrosis has significantly increased pulmonary edema 
(Figure 30B, D) and pleural thickness (Figure 30A, C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Increased edema and lung damage in lung fibrosis and lungs of mice with kidney fibrosis. A) 
Representative images of pleural thickness in the lungs of mice from each cohort. B) Representative images of 
alveolar and pleural edema from the lungs of mice from each cohort. C) Quantification of pleural thickness from the 
lungs of mice from each cohort. D) Quantification of alveolar and pleural edema from the lungs of mice from each 
cohort. N=6 for Healthy, wound, PBS, Bleomycin, sham, and UUO. N=3 for Angiopeotin-2 cohort. Images taken at 
63X. Data are represented as the mean ±SEM using Student’s T-test for *p < 0.05, **p < 0.01, ****p < 0.0001. ns, 
not significant. 
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Lung and kidney endothelial response to Angiopoietin 2 treatment in vitro 
Using two in vitro endothelial cells lines isolated from the lungs and kidneys of an 
SV-40 T-antigen mouse we tested the response to Angiopoietin 2 to determine if they had a 
differential effect. While the predominance of previous studies used HUVECs to study 
endothelial response in vitro, here we used endothelial cells isolated directly from the 
organs of interest. HUVECs were isolated from umbilical cord cells which are not shown to 
form metastatic disease, as compared to the lungs. This allowed us to compare the 
response of lung and kidney endothelial cells when exposed to Angiopoietin 2. By treating 
both cell lines with 1ug of Angiopoietin 2 we then immunofluorescently stained the cells for 
Phalloidin and ZO-1. Although previous publications have shown response in HUVECs as 
low as 400ng of Angiopoietin 2, we opted to use 1ug to ensure sufficient response of the 
treated cell lines. The non-treated cell lines received PBS vehicle. ZO-1 costained with 
Phalloidin permitted visualization of cellular borders and was additionally confirmed with 
bright field imaging. The visualization of the cellular borders is necessary for ZO-1 analysis 
as the tight junction complex is located between cells, with ZO-1 localizing to the cell 
membrane to bind the transmembrane proteins that form the tight junction.   
Analysis of ZO-1 localization in non-treated and treated lung endothelial cells clearly 
indicated that after 30 minutes of Angiopoietin 2 treatment ZO-1 delocalized from the 
endothelial cell membrane (Figure 31A, B). As ZO-1 is a critical protein in the formation of 
the tight junction complex this indicates that lung endothelium become destabilized when 
exposed to Angiopoietin 2.  
Furthermore, by performing western blot analysis for phosphorylated Tie-2 Tyr1108 
on cells treated with Angiopoietin 2 we clearly show that while the lung endothelial cells 
react rapidly to the treatment, within 45 minutes to an hour they have returned to basal 
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levels (Figure 31C). This fast reaction and return response indicates that once Angiopoietin 
2 returns to basal levels in circulation the vasculature will rapidly stabilize. Conversely, with 
chronically elevated circulating Angiopoietin 2 levels the vasculature will be unable to 
stabilize and the lung endothelium will lose functioning tight junctions. The result of which 
will be increased vascular permeability and increased potential for circulating tumor cells to 
extravasate. Furthermore, there was a direct activation and increase in pERK which 
coincided with the pTie2 in the lung endothelial cells treated with Angiopoietin 2 (Figure 
31C). 
Upon testing kidney endothelial cells, we found that their ZO-1 did not delocalize 
from the membrane upon Angiopoietin 2 treatment (Figure 31D, E), although their levels of 
pTie-2 responded rapidly within the first 5 minutes but decreased after that (Figure 31F). 
Furthermore, the changes in pERK observed in the lung endothelial cells did not occur in 
the kidney endothelial cells (Figure 31F). These results indicate that renal and lung 
endothelial cells appear to react in a dissimilar manner when exposed to Angiopoietin 2. 
Given that we reported that in vivo we observed no vascular leakage in the kidneys of mice 
treated with Angiopoietin 2, this indicates that the vasculature responds in an organ-specific 
manner.  
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Figure 31: ZO-1 delocalized in lung endothelial cells, but not renal endothelial cells when treated with Angiopoietin 
2 in vitro. A) Representative images of ZO-1 expression and membrane localization in lung endothelial cells treated 
with PBS or Angiopoietin 2. B) Quantification of ZO-1 membrane localization in lung endothelial cells treated with 
Angiopoietin 2. N=3 C) Western blot showing phosphoTie-2 Ty 1108, and p-ERK in lung and renal endothelial cells 
treated with Angiopoietin 2 at 5, 15, 30, 45 and 60 minutes. Actin is the control. D) Representative images of ZO-1 
expression and membrane localization in renal endothelial cells treated with PBS or Angioppoetin-2 E) 
Quantification of ZO-1 membrane localization in renal endothelial cells treated with Angiopoietin 2. N=3 F) Western 
blot showing phosphoTie-2 Ty 1108, and p-ERK in renal endothelial cells treated with Angiopoietin 2 at 5, 15, 30, 
45 and 60 minutes. Scale bar=5um. Data are represented as the mean ±SEM using Student’s T-test for *p < 0.05, 
**p < 0.01, ****p < 0.0001. ns, not significant. 
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Organ specific tight junction response to Angiopoietin 2 treatment 
As our in vitro results indicated that lung and kidney endothelial cells responded with 
a dissimilar delocalization of ZO-1 upon Angiopoietin 2 treatment, we surmised that an 
aspect of the vasculature must be responsible for organ-specific response to Angiopoietin 2 
and the fibrotic environment. Given that capillaries are the predominant vascular structure 
we hypothesized that pericytes and tight junctions may respond in differential manners 
when endothelial cells are exposed to varying circulating cytokines. As capillaries do not 
possess smooth muscle and have been shown to be regulated by pericyte activity we 
choose to focus on the tight junction and pericyte response to fibrosis.  
As fibrotic lungs enhanced metastasis, and fibrotic kidneys did not reroute 
metastasis, but did enhance it to the lungs we compared gene expression by Illumina array 
of healthy lungs versus healthy kidneys, healthy and fibrotic lungs, and healthy and fibrotic 
kidneys. The purpose of these comparisons was to determine how tight junction and 
pericyte gene expression response was differentially expressed in the healthy organs, and 
how the response was different in the fibrotic lung versus the fibrotic kidney. We 
hypothesized that gene signature differences in the fibrotic lung compared to the kidney 
fibrosis may be responsible for the organ specific vascular response. We also analyzed the 
gene expression level differences between healthy lungs and healthy kidneys to determine 
if either organ was more dependent on a specific tight junction. As vascular permeability is 
directly related the expression of tight junction proteins we analyzed the differential levels of 
claudins, occuludin, the junction adhesion genes, the zonula occludin genes, and genes 
known to be associated with pericytes.  
The gene expression analysis revealed significantly different organ specific 
responses to fibrotic insult within the fibrotic lung and kidneys. Analysis revealed that 
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Claudin-5 expression decreased in the fibrotic lung, while it was increased in the fibrotic 
kidney (Figure 32A, B, C). The importance of the differential changes in Claudin-5 
expression were of particular interest given its role in the formation of tight junctions and 
that is considered a key protein in endothelial tight junction barrier formation and modulation 
of vessel permeability. Furthermore, we found that the expression of the Angiopoietin 2 
receptor Tie 2 TEK gene expression in the healthy kidneys was significantly lower than in 
the healthy lungs (Figure 32D), indicating that Angiopoietin 2 would affect endothelium at 
different levels in the lung as compared to the kidneys. It is also possible that given the 
chemotactic relationship between Tie 2 and Angiopoietin 2 that the circulating cytokine 
moves more towards the lungs.  
An analysis of the genes associated with pericytes noted no significant change in 
desmin in the fibrotic lungs, but a significant increase in desmin in the fibrotic kidneys 
(Figure 32A). Similarly, there was no significant change in PDGFRb in the fibrotic lungs, but 
an increase in the fibrotic kidneys (Figure 32A). Finally, there was no significant change in 
NG2 expression in either the fibrotic lung or the fibrotic kidneys (Figure 32A). Furthermore, 
there was a significant decrease in the expression of Endothelin-1 in the fibrotic lungs while 
the fibrotic kidneys showed a significant increase (Figure 32A). This is of interest given that 
Endothelin-1 is synthesized and secreted by the endothelial cells and its known receptor is 
expressed by pericytes. These differential responses indicate that the vasculature responds 
differently in each organ and there is a thus a differential pericyte response.  
These results indicate that pro-tumorigenic factors will illicit different responses in the 
lung versus the kidney vasculature. The differential response functionally results in either 
increased vascular permeability in the lung, or decreased vascular permeability in the 
kidney. In the context of breast cancer, the increase in pulmonary vascular permeability 
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enhances metastatic extravasation. Conversely a decrease in kidney vascular 
permeabilization in the presence of pro-fibrotic factors prevents the extravasation of 
circulating tumor cells and thus makes the kidney a rare organotropic organ in breast 
cancer metastasis. 
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Figure 32: Lung and kidney fibrosis show different expression of tight junction proteins. A) Heatmap of probes 
for genes associated with tight junctions. Probes fluorescent units are shown in log scale. B) qPCR for Cldn-5 
in a healthy versus a fibrotic kidney. N=3 C) qPCR for Cldn-5 in a healthy versus fibrotic lung. N=3. D) qPCR 
for TEK with 2 different primers sequences N=3. Data are represented as the mean ±SEM using Student’s T-
test for *p < 0.05, **p < 0.01, ****p < 0.0001. ns, not significant. 
 
 
 
 
 
 
Healthy 
Lung
Healthy 
Kidney
Healthy 
Lung
Fibrotic 
Lung
Healthy 
Kidney
Fibrotic 
Kidney
Cldn1 1.725855 2.074025 1.885439 1.714346 2.067155 2.553294
Cldn10 1.042846 3.078517 3.240388 2.995372 3.090022 2.375598
Cldn10 2.511397 3.353452 2.521146 2.391559 3.157074 2.860594
Cldn10 3.30153 3.92243 2.48997 2.398397 3.36834 3.228519
Cldn11 1.634065 2.084433 1.822978 1.696733 2.081764 2.088335
Cldn12 2.746894 2.937576 2.73344 2.70825 2.945622 3.040753
Cldn15 1.691578 2.063898 2.15183 2.055265 0.987007 1.223858
Cldn15 1.0673 0.816479 1.861464 1.827238 2.237179 2.278022
Cldn15 2.070511 2.239789 1.548988 1.542584 2.056685 2.021418
Cldn17 0.806782 1.32002 1.494456 1.627767 1.363203 1.224303
Cldn18 3.63973 1.475166 3.551911 3.533167 1.492079 1.242415
Cldn2 1.50254 3.714192 1.763974 2.092983 3.702203 3.589471
Cldn2 1.396213 3.678132 1.724853 2.033223 3.742804 3.706964
Cldn22 0.95499 0 1.524659 1.529774 0.823584 1.195657
Cldn23 2.122793 1.418509 2.19241 2.109129 1.448946 1.721983
Cldn3 3.092966 2.077739 3.050777 3.04431 2.071095 2.775268
Cldn4 1.784237 2.460485 1.933699 3.179943 2.461372 3.524926
Cldn5 3.880881 2.353398 3.775064 3.624527 2.352868 2.557851
Cldn6 1.068859 1.723275 1.548492 1.62667 1.716628 2.26922
Cldn7 1.861838 1.808166 1.984234 1.841974 1.794374 2.042458
Cldn9 1.839134 1.906491 1.966761 1.777399 1.894351 1.737368
Cldnd1 2.253058 2.039226 2.299504 2.307267 2.030638 2.17443
Tjp1 2.423483 1.729211 2.443944 2.369735 1.717069 1.990335
Tjp2 2.845738 2.395895 1.551893 1.646987 2.396045 2.500615
Tjp3 1.723243 1.618194 1.905523 1.850072 1.614201 1.818549
Tjp3 1.757639 1.726899 1.881675 1.897495 1.715031 1.891542
Ocln 2.080158 2.148476 2.157223 2.012169 2.144246 2.187372
Jam2 1.719204 0.904621 1.773629 1.879762 1.042712 1.254139
Jam2 1.569251 1.090264 1.806081 1.855982 1.086846 1.251948
Jam2 1.619956 0.96338 2.182666 2.203421 1.503235 1.438369
Jam2 2.110813 1.486255 1.87785 1.891496 1.178643 1.12545
Jam3 1.123475 1.318572 1.56855 1.595902 1.362949 1.16336
Jam4 2.47842 3.131161 2.491212 2.808383 3.144961 3.087373
Edn1 3.198908 1.719981 3.144331 2.924457 1.716141 2.745697
Des 3.19052 2.167121 3.205549 3.117294 2.163552 2.447314
Pdgfrb 2.278738 1.693994 2.321405 2.2927 1.687429 2.268804
Cspg4 1.875004 1.946552 1.994376 1.864685 1.935633 1.801706
Anpep 2.395541 2.747236 2.419269 2.090828 2.752616 2.563633
Acta2 2.395541 2.747236 2.625435 3.188125 2.112624 2.736601
Lox 2.557703 1.076554 2.560553 3.624162 1.172391 2.466386
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Chapter 7: Anti-Angiopoetion-2 rescues the metastatic enhancement effects of 
kidney fibrosis 
 As we have identified Angiopoietin 2 as a factor secreted by the fibrotic kidney, and 
as it has also been implicated in other vascular related pathologies we next wanted to 
determine whether treatment of mice 1) with recombinant murine Angiopoietin 2 and 
injected intravenously with 4T1 cancer cells or 2) with Angiopoietin 2 antibody peptide that 
had both kidney fibrosis and breast cancer could rescue the enhanced metastatic 
phenotype. Mice injected with recombinant murine Angiopoietin 2 one day prior and one-
day post intravenous injection with 4T1 cancer cells (Figure 33A) showed significant 
increase in colonization of the lungs (Figure 33B, C, D). We then utilized the orthotopic 
model either given control IgG or treated with the Angiopoietin 2 peptide. Mice treated with 
IgG had either no kidney fibrosis or kidney fibrosis, and similarly mice treated with the 
Angiopoietin 2 peptide had either kidney fibrosis or no kidney fibrosis. In the mice the 
control group treated with IgG we saw an increase in metastasis to the lungs similar to the 
previous phenotype in Figure 21 (Figure 33F, G, H). When the mice where treated with the 
Angiopoietin 2 peptide we saw the metastatic burden in the lungs of mice kidney fibrosis 
return similar levels of mice without kidney fibrosis (Figure 33F, I, H). These results indicate 
that Angiopoietin 2 was a key factor in the enhancement of metastatic spread and 
colonization of lungs in mice with kidney fibrosis.  
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Figure 33: Anti-Angiopoetin 2 Antibody in Tumor Bearing mice with Kidney Fibrosis Reduces Lung Metastasis to 
Levels of Mice without Kidney Fibrosis. A) Schematic of time course treatment with recombinant murine 
Angiopoietin 2 and injected intravenously with 4T1 cancer cells. B) Quantification of colonization of the lungs of 
mice treated with PBS or recombinant murine Angiopoietin 2 and injected intravenously with 4T1 cancer cells. N=6. 
C) Quantification of surface lung nodules of mice treated with PBS or recombinant murine Angiopoietin 2 injected 
intravenously with 4T1 cancer cells. N=6. D) Representative images of the lungs of mice treated with either PBS or 
recombinant murine Angiopoietin 2 and injected intravenously with 4T1 cancer cells. Scale bar=25 um. E) Tumor 
volume measurements over time in orthotopic tumors with sham or UUO and either treated with IgG or anti-
Angiopoietin 2. Two-way Anova with Tukey’s multiple comparison test was used. F) Quantification of the metastatic 
area of the lungs of the indicated groups. N=8 per group. One-Way Anova was used. G) Representative images of 
lungs of mice with either sham or UUO treated with IgG. Scale bar=25 um. H) Quantification of the number of 
surface lung nodules in the indicated groups treated with IgG. N=8 per group. I) Representative images of lungs of 
mice with either sham or UUO treated with anti-Angiopoietin 2. Scale bar=25 um. J) Quantification of the number of 
surface lung nodules in the indicated groups treated with anti-Angiopoietin 2. N=8 per group. Data are represented 
as the mean ±SEM using Student’s T-test unless otherwise noted. *p < 0.05, **p < 0.01, ****p < 0.0001. ns, not 
significant.  
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Summary of Results 
Herein we set out to determine the role of the fibrotic environment in the 
determination of breast cancer metastatic organotropism. By showing the significant 
similarities between the fibrotic lung and kidney for factors previously associated with the 
pre-metastatic niche and organotropism we developed a way to test the contribution of 
these factors on metastatic tropism. As expected the fibrotic environment in a tropic organ 
enhanced metastasis to that organ. However, despite previous evidence implicating the 
growth factors in the control of metastatic spread we did not see any metastasis to the 
fibrotic kidney. None the less the fibrotic kidney did enhance metastatic spread to the lungs. 
This led us to hypothesize that there was an alternative organ specific alteration that 
occurred due to the secretion of pro-tumorigenic fibrotic factors into circulation. We 
identified Angiopoietin 2 as a cytokine that is found to be upregulated in the circulation of 
fibrotic kidney disease. Previous research has also shown that Angiopoietin 2 is 
upregulated in patients with breast cancer and is prognostic of decreased disease free 
survival. By treating mice with Angiopoietin 2 we observed an organ specific vascular 
response leading to increased vessel permeability in the lungs, and a converse reaction in 
the kidneys. Further analysis revealed that there is an organ specific vascular response 
mediated by the expression of the tight junction protein Claudin-5. Finally, by treating tumor 
bearing mice that had fibrotic kidney damage with recombinant murine Angiopoietin 2 we 
showed that the enhanced metastatic phenotype could be enhanced, and it could be 
rescued by treating tumor bearing mice with kidney damage with anti-Angiopoietin 2. 
Together, our results show for the first time that organotropism is due to an organ specific 
vascular response to increased levels of circulating cytokines.  
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Chapter 8: Summary and Discussion 
The recognition that primary tumors have specific tropism for metastatic spread has long 
been an area of research (Fidler 2003) in the hopes of determining the mechanisms that 
control metastasis. The ultimate goal being the development of therapies aimed at treating 
and preventing metastasis. Given the fact that modern therapies are all but unable to treat 
metastatic disease and the poor prognosis associated with the diagnosis, this continues to 
be a high priority in cancer research. Since Virchow, Paget and Ewing (Talmadge and Fidler 
2010) first began the study of metastatic disease the predominant focus of research has 
been to ask why cancer has tropism for specific organs. Given the failure of this approach to 
determine the mechanistic control of organotropism we choose to approach this issue from 
an alternative viewpoint. In this study we focused on not only asking why cancer spreads to 
the tropic organ, but also why it does not spread to non-organotropic organs. By developing 
a pro-tumorigenic environment in both a tropic and non-organotropic organ for two 
commonly used breast cancer metastasis models, we were able to elucidate the 
contribution that this environment plays in directing metastatic spread. This also allowed us 
to identify that an organ-specific vascular response to increased pro-tumorigenic cytokines 
may in fact be a key determining mechanism in organotropism of metastatic disease. 
Although it is considered common medical knowledge that organs have different structural 
vascular mechanics (Junqier Histology), the finding that organ-specific vasculature 
responds differently to the same cytokines, is a novel finding and may pave the way for the 
research and development of organ-specific therapies not only for cancer related diagnosis 
but also for organ specific pathologies.  
The Unusual Suspects; Organotropism is not determined by previously published 
factors complicit in the pre-metastatic niche 
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While it has commonly been published that the tumor microenvironment, the pre-metastatic 
niche and the fibrotic environment are considered similar (Arwert, Hoste and Watt 2012), 
the ability of this environment to direct metastasis has not been truly tested. If these 
environments are all biochemically and biophysically similar, then the induction of fibrosis 
should enhance metastatic spread regardless of the organ of damage. Although some 
research has been done to show that the fibrotic environment can enhance metastasis 
(Erlner 2016), this has only been done in organs that are already tropic for that primary 
tumor. While this is relevant research, it does not fundamentally test the ability of the known 
pro-tumorigenic fibrotic factors to actually direct metastasis. If the fibrotic factors are the 
determinants of organotropism then regardless of location, when significantly upregulated, 
metastasis should spread to that organ. However, we clearly show here that that is not the 
case. This finding indicates that while these pro-tumorigenic fibrotic factors are able to 
enhance metastasis they are insufficient in directing organotropism. This indicates that 
alternative factors are the source of the mechanism of organotropism. While our model of 
surgically induced kidney fibrosis and chemically induced lung fibrosis do show increases in 
fibrotic factors it is important to note that the induction methods may elicit different fibrotic 
development. The surgically induced fibrosis causes an increase in shear stress in the 
proximal tubules due to an increase in pressure from un-excreted filtrate. This increase in 
continued shear stresses leads to proximal tubule damage and the chronic release of 
fibrotic factors ultimately leading to kidney fibrosis. While the chemical induction in the lungs 
is a response to the DNA damage agent bleomycin leading to an increase in epithelial cells 
releasing pro-fibrotic factors. It is possible that the different methods of induction elicit 
different responses. Nonetheless, we clearly show that the factors implicitly believed to be 
the controlling factors for organotropism are upregulated in both our lung and kidney fibrosis 
models. Given that the kidney fibrotic environment could not re-route metastasis we 
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concluded that alternative factors must be responsible for the control of organotropism. This 
result would indicate a paradigm shift as it clearly indicates that the pre-metastatic niche, 
that is significantly similar to the fibrotic environment is not sufficient to direct metastatic 
spread. While this indicates that the fibrotic factors are not responsible for directing 
organotropism, it does not mean that they are not responsible for the enhancement of 
metastasis. In fact, our findings profoundly support previous studies showing that these 
factors are pro-tumorigenic for metastatic enhancement.  
 
The seed grows where you want, you just have to put it there. 
In addition to the pre-metastatic niche being implicated in the determination of 
organotropism, the currently held belief for organotropism is that disseminated cancer cells 
only grow in specific organs based on Paget’s seed and soil hypothesis. However, previous 
publications have shown that murine cancer cell lines that are known to be organotropic for 
specific organs can grow in non-organotropic organs. The key example of this would be the 
growth of 4T1 or B16-F1 cells in the kidneys of mice injected under hydrostatic pressure (Li 
and Liu 2011), and 4T1 cells directly injected into either the renal capsule or the cortex 
(Daniel Guimarães Tiezzi 2013). In these experiments a mammary fat pad cancer cell line 
that does not typically metastasize or colonize the kidney successfully grew in the kidneys. 
Physiologically, the only key system that is bypassed by these experiments is the vascular 
system. In the hydrostatic model they cause systemic vascular permeabilization by 
mechanistically overloading the osmotic pressure within the vessels. The direct injection 
models bypass the vascular system by simply being directed into the parenchymal 
perivascular spaces. Regardless of the method, the important point here is that these cell 
lines successfully grew in the kidneys when the vascular system is not an obstacle. By the 
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process of elimination, it is clear that the vasculature is an essential barrier to metastatic 
growth. However, the endothelial layer is a barrier to extravasation systemically, not just in 
the kidneys. In the lungs circulating cancer cells must also extravasate. Yet, under 
conditions where the primary tumor is grown orthotopically or injected intravenously under 
normal hemostatic pressures these cancer cells only grow in the lungs and other tropic 
organs. This indicates that the vasculature of different organs may behave differently 
depending on the organ. Observations supporting this is that lung fibrosis and kidney 
fibrosis release different levels of circulating Angiopoietin-2. While previous studies have 
shown that there is less Angiopoietin-2 expressed in the lungs as compared to the kidneys 
at basal non-pathological levels (Gale and Yancopoulos 2002), our results indicate that this 
is also true in the pathological state as well. Additionally, our Illumina array study comparing 
fibrotic lungs to healthy lungs showed that Angiopoietin 2 expression decreased significantly 
in the fibrotic lungs. There are many possible reasons for this and they are most likely 
related to the specific functions of the two organs. The lungs most likely have lower basal 
levels of Angiopoietin 2 as increased pulmonary vascular permeability would not be 
conducive to the organism as a whole and is generally restricted to tip cells in the lungs 
(Feltch 2012). Conversely, changes in vascular permeability in the kidneys under the control 
of Angiopoietin 2 might be useful for angiogenesis and also for the increased permeability of 
molecules required for reabsorption into circulation. Interestingly, a recent paper studying 
cerebral cavernous malformations found that increased levels of Angiopoietin 2 show a 
decrease in Claudin 5 expression in the brain (Zhou 2016). Given that breast cancer is 
known to metastasize to the brain, this indicates that Angiopoietin 2 has a similar vascular 
permeability mechanistic effect on both the lungs and brain lending further evidence to the 
organ specific responses to Angiopoietin 2. This further evidences a differential response to 
the same cytokine under similar pathological conditions. We induced fibrosis in both lung 
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and kidneys, and yet the lungs showed a different vascular response than did the kidneys, 
despite the fact that pro-tumorigenic factors where increased in both organs.  
The organ-specific vascular response was further evidenced by the differences in vessel 
permeability as observed when mice where treated with Angiopoietin 2 and FITC-Dextran 
and the response of the organ-specific cell lines. Similar to publications showing that 
increased circulating Angiopoietin 2 induces pulmonary edema and increased lung vascular 
permeability (Parikh and Sukhatme 2006) we also noted the same, but no such change in 
the kidney. This was mirrored in the in vitro studies. When taken together with the evidence 
that increased expression of Angiopoietin 2 is correlated with a poor disease-free prognosis 
in breast cancer patients, this indicates that the fibrotic cytokine Angiopoietin 2 specifically 
causes vessel leakage in the lungs, but not in the kidneys.  
While Angiopoietin 2 is only one of many pro-tumorigenic cytokines released into circulation 
it is the observation that it elicits an organ-specific response that is most important. The next 
step in this area of research would be to test the vascular effects of injecting mice with pro-
tumorigenic factors such as TGFb, TNFa etc. Given that many of these cytokines are 
upregulated in the circulation of patients with tumors, it may be that the organ vascular 
response is what determines organotropism by vessel permeability. Taken a step further it 
may also be that the endothelial vessel response is specific in other mechanistic properties 
as well. For example, the expression of ICAM1 and VCAM1 by endothelial cells induced by 
the increased presence of pro-tumorigenic factors in circulation is a key mechanism for the 
binding of lymphocytes to endothelial cells for diapedesis. Given that we show that 
endothelial cells can respond differently, it is plausible that different organ endothelial cells 
may express different membrane receptors when exposed to pro-tumorigenic cytokines that 
better enable the binding of circulating tumor cells to the endothelial lumen and increase 
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their ability to cross into the perivascular space (Nolan 2013). Our finding also highlights the 
need to determine the specific cytokines that are released by differing primary tumors. If all 
primary tumors released the same cytokine profile, then one would surmise, based on our 
findings, that they would all have similar organotropism. However, it is known that that is not 
the case (Drandoff 2004). Therefore, we would surmise that different primary tumors, and 
possibly even tumors with different genetic mutations would have a different circulating 
cytokine profile. This differing circulating cytokine profile may therefore affect only some 
organs in a manner that makes them more susceptible to metastatic spread.  
 
It is all tight junctions all the time 
An area of study that is woefully under researched is the tight junctions that exist between 
endothelial cells. To date only Claudin-5 has been identified as a tight junction claudin 
involved in endothelial cells. The remaining proteins involved in the tight junctions of the 
endothelial cells have not been pursued in depth. Given that tight junctions are a key 
complex in the formation of the vascular barrier and cell-cell contacts, this is an area that 
requires more focus. Furthermore, similar to the claudin heterogeneity found in epithelial 
cells, this is likely an organ-specific difference that will be key in determining organ 
responses to circulating cytokines in both normal and pathological states (Nolan 2013). 
Given the endothelial mouse models that exist today, this area of research is more 
accessible than it was previously. The development of Tie-1, Tie-2, and CDH5 Cre mice 
tagged with a fluorescent promoter would allow the visualization and or Fluorescent 
Activated Cell Sorting sorting of these cells from specific organs to determine by both qPCR 
and protein staining the expression of the different proteins involved in tight junction 
complex formation (Nolan 2013). While we identified an organ-specific response for the 
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endothelial Claudin-5 tight junction complex, it is unlikely that this is the only claudin, or JAM 
implicate in the formation of endothelial tight junctions. Identification of the proteins that are 
differently required in each organ will open the door for possible organ-specific therapies. A 
good example of this would be with the blood-brain barrier. The main issue behind treating 
cerebral pathologies is that the blood-brain barrier is often impenetrable by drugs injected 
intravenously. The determination of the specific tight junction proteins involved in this barrier 
may allow for the momentary increase in cerebral vessel permeability with co-treatment of 
drugs typically unable to cross the blood-brain barrier. This will also allow for the 
development of new therapies and determination of adverse effects. For example, in the 
mice we treated with anti-Angiopoietin 2 we noted that there was a decrease in metastatic 
lung disease. Given our research into the kidney we could hypothesize that there would be 
limited to no negative renal effects. Given that currently there are trials for anti-Angiopoietin 
2 therapy for cancer patients, this is an important finding.  
In addition to cancer, this also holds vital findings for other systemic pathologies. As 
previously mentioned, patients with sepsis are commonly affected by pulmonary issues, 
including but not limited to pulmonary edema. Basic science research has linked this to 
excess Angiopoietin 2 in circulation. Furthermore, a less well studied pathology known as 
uremic lung also results in both alveolar and pleural pulmonary edema. Uremic lung occurs 
in patients who have either acute or chronic renal damage. It was noted that in the 1940s, 
during World War II, patients with kidney damage often required ventilators due to breathing 
issues. This was originally believed to be related to hypervolemia, and thought to resolve 
with the advent of dialysis. However, this was not the case and uremic lung still possess an 
issue for patients with renal damage today. In both these cases, the excess of circulating 
Angiopoietin 2 occurred in an unrelated organ and yet significantly adversely affected the 
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lungs. By focusing research on which cytokines affect which organs in what specific 
manners we can begin to develop focused therapies to combat organ specific disease.   
 
 
Multiple factors affecting organotropism 
While our research has shown that the previous factors implicated in the pre-metastatic 
niche and fibrotic environment are able to enhance metastasis, they are not able to direct 
organotropism as previously believed. Furthermore, we implicate the vasculature in 
organotropism and show that organ-specific vascular responses to circulating cytokines 
may illicit organ-specific responses. Our research, taken in the context of previous 
publications, indicates that metastatic organotropism is likely a process that is based on the 
following three fundamental factors: 
1) Primary tumor releases multiple subpopulations of circulating tumors cells that 
have differing ability to cross organ-specific endothelial barriers. 
2) Primary tumor releases specific cytokine signature that systemically travel 
through circulation but affect different organ vasculature in different manners 
causing organ-specific alterations in endothelial behavior making specific organs 
susceptible to metastasis.  
3) Tumor secreted cytokines affect different organ environments in different 
manners enhancing metastatic potential.  
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